ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0007253;cytoplasmic sequestering of NF-kappaB;13.0;1.0;0.9625549647676366;9.628524252492122;578.6196231821564;7.8311634786251565;0.019365878064054164;0.8630410292508717;[NFKBIA, CCDC22]
GO:1901222;regulation of NIK/NF-kappaB signaling;7.0;0.8436909121759173;0.7727648213451592;9.34084218004034;45.070113835906206;5.223196736079928;0.001508456149618737;0.6180338892438164;[TNF, HAVCR2, ACTN4, IL1B, CHI3L1, TLR7, TLR4, TLR2, NLRP3, CCL19, TNFSF14, TNFRSF10B, NFKBIA, NLRP12, IL18R1]
GO:0032691;negative regulation of interleukin-1 beta production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;85.92712208559752;6.781341354126479;0.002875903446815721;0.6977174774718518;[GHSR, NLRP3, TNFAIP3]
GO:1901224;positive regulation of NIK/NF-kappaB signaling;8.0;0.9326813400603323;0.8413406700301662;9.571365838652174;238.82315740091596;5.572381008289503;0.007993196151321231;0.6599718239061428;[TNF, HAVCR2, ACTN4, IL1B, CHI3L1, TLR7, TLR4, TLR2, CCL19, TNFSF14, TNFRSF10B, NLRP12, IL18R1]
GO:0007254;JNK cascade;11.0;1.0;0.9324289523296623;9.628524252492122;290.6144555783003;5.926926025970411;0.009726604292176047;0.735532224928036;[TNF]
GO:0051092;positive regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.4401483168805;4.8283137373023015;0.009352610284359957;0.6950405016553352;[TNF, PYCARD, TNFSF11, BTK, S100A8, TNFRSF11A, NLRP3, TGFB1, NFKB1, CD36, TRAF1, IL1B, TLR4, LTF, TLR2, NLRC4]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[NRP1, CDH5, C3AR1, GHSR, ANXA1, ANXA3, GAB1, IL1B, ADAM12, AGTR1, CHI3L1, ENG, CX3CR1, C5AR1, PTGS2, DLL1, CXCR2, JUP, PLK2, TNFSF12, LRG1, TEK]
GO:0000188;inactivation of MAPK activity;13.0;0.8436909121759173;0.8844004208555951;9.558319993818873;2610.871803759405;6.518977089658987;0.08738352963975493;0.7959357562962344;[DUSP2, DUSP1, CAV1, DUSP6, PPP2R1A]
GO:0000187;activation of MAPK activity;13.0;0.811012628672052;0.8680612791036626;9.526741558182179;3706.2450018205795;4.759793790865545;0.12404468480698592;0.705971040585548;[, LRRK2, TNF, GHR, PROK2, TNFSF11, MAP4K1, MAP2K2, DUSP6, IL1B, KIT, TLR4, C5AR1, FPR1, CXCR4, TGFA, IQGAP3, CCL19, DRD4, EGF, CSPG4, PKN1]
GO:0050796;regulation of insulin secretion;9.0;0.8259837884571596;0.8092325194088689;9.533214072687796;205.48125160941495;4.61801832846594;0.006877272570246766;0.6324062972578516;[KCNG2, TNF, GHSR, IFNG, IL1B, BLK, CNR1, CCL5]
GO:0000185;activation of MAPKKK activity;13.0;0.8259837884571596;0.8755468589962163;9.54300207905396;3706.2450018205795;6.8867018697843045;0.12404468480698592;0.814741218652794;[MAP4K1, TNF]
GO:0048247;lymphocyte chemotaxis;7.0;0.7671156992804218;0.7344772148974115;9.303101852057495;94.37808318069546;5.926926025970411;0.003158749509297446;0.6540226378555745;[CCL13, CXCL9, CCL23, CCL20, DEFA1, CXCL13, CXCL16, CXCL10, CXCL11, CCL8, CCL7, CCL5, CCL4, CCL2, XCL1, CCL1, CCL19, CCL18, CCR2]
GO:0030949;positive regulation of vascular endothelial growth factor receptor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;213.0397923327438;7.069023426578259;0.0071302501260115695;0.7124295520356204;[IL1B]
GO:0070164;negative regulation of adiponectin secretion;9.0;1.0;0.896240625180289;9.628524252492122;854.5051635618736;8.390779266560578;0.028599518819696718;0.8253454670833372;[IL1B]
GO:0048245;eosinophil chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;130.2972973825895;6.7325511899570465;0.004360933283440787;0.740543606130341;[LGALS3, CCL13, CCL23, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1]
GO:0000060;protein import into nucleus, translocation;9.0;1.0;0.896240625180289;9.628524252492122;93.4429707305496;6.444869117505266;0.0031274521371376313;0.7258315315665724;[TGFB1, PHB2, TNF, NFKBIA, POLA2, BCL6, IFNG, AKT1, RAN]
GO:2000352;negative regulation of endothelial cell apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;129.9263443150347;6.444869117505266;0.0043485178181058145;0.7258315315665724;[TNFAIP3, TEK]
GO:0097527;necroptotic signaling pathway;5.0;1.0;0.7902410118609202;9.628524252492122;23.17027026302992;7.9853141584524145;7.75488093814194E-4;0.6986103492792611;[FASLG, TNF]
GO:0051403;stress-activated MAPK cascade;10.0;0.811012628672052;0.8207473261969463;9.451593544333043;288.8226961090722;5.500407508664414;0.009666635715219814;0.696532107649126;[TNF, NFKB1]
GO:0060355;positive regulation of cell adhesion molecule production;5.0;1.0;0.7902410118609202;9.628524252492122;40.679961272662325;8.390779266560578;0.0013615216942077584;0.7193458537639684;[COLEC12, CAV1, IL1B]
GO:0065003;protein-containing complex assembly;4.0;0.45485133202666184;0.4774256660133309;6.058991556010752;36.471478728154885;2.4440506132939883;0.0012206675708314864;0.3749888620238313;[, NUP107, CLDN3, PADI4, PDGFC, ABCA1, JUP, ARHGAP6, CHAF1B, CHAF1A, KCND2, ARG1, F5, SLC7A7, HLA-DMA, HLA-DMB, DMD, CENPK, CENPL, GOPC, KCNG2, GMNN, RUVBL1, OLFM4, BLM, LIN7A, CXCL12, HLA-DRA, LRRK2, VBP1, NDUFC2, ACPP, NDUFB6, HM13, NDUFB4, NDUFB3, NDUFB2, NDUFB1, CCL5, NDUFA8, NDUFA6, NDUFA3, NDUFA2, IL2RB, EIF3D, CCNH, TCL1A, SNRPD2, SNRPD1, TNFSF11, FBXO5, SNRPD3, MIF, TGFA, PTK2, CD3G, CD3E, CCT3, CCT2, MIS12, CCT8, GCH1, RPA1, RPA3, NDUFAB1, NDUFB10, NDUFB11, H1FX, CAV2, CAV1, HMGA1, NASP, TCF4, HMGB2, TNFAIP3, NUP62, NDUFS8, NDUFS7, NDUFS4, NDUFS3, NUP54, FBP1, SAMHD1, EGF, TTC19, TEK, CDA, NUP205, ACMSD, BRD2, GSN, GTF2H1, TNF, DACH1, MEN1, TLE4, SNRPG, SNRPE, SNRPF, NACC2, LSM3, TRAF1, MCM2, NLGN1, NLRC4, PLN, RAD51, P2RX1, PPP2R1A, MCCC2, TLN1, MGST1, CD79B, CD79A, AHCTF1, RAD51C, UQCR10, NDUFA11, KNTC1, CHRNB4, ADRB2, NLRP3, MYH11, TGFB1, DNM2, TGFBR3, COLEC12, HIST1H2BK, HSPD1, REPS2, RBMX]
GO:2000010;positive regulation of protein localization to cell surface;7.0;1.0;0.8509193652572005;9.628524252492122;73.70707873031733;7.004484905440688;0.002466909593039506;0.7091290490632969;[TNF, AKT1]
GO:0045410;positive regulation of interleukin-6 biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.3044735649636;7.8311634786251565;0.02792341990494083;0.7754860644832351;[TLR1, IL1B, PTAFR]
GO:0042267;natural killer cell mediated cytotoxicity;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;47.356962503066434;6.7325511899570465;0.001584994916478408;0.6674232935401965;[KLRK1, SLAMF7, KIR3DL1]
GO:0045779;negative regulation of bone resorption;7.0;1.0;0.8509193652572005;9.628524252492122;83.00611842489866;7.292166977892469;0.002778140083024753;0.7238411236270654;[TNFAIP3]
GO:0045416;positive regulation of interleukin-8 biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.8798377098682;7.474488534686424;0.027942676825076673;0.7572456912631272;[TLR8, TLR7, TLR4, TNF, ELANE]
GO:0033092;positive regulation of immature T cell proliferation in thymus;11.0;1.0;0.9324289523296623;9.628524252492122;1868.4618253278568;8.67846133901236;0.06253573578725322;0.8762458687964789;[IL1B]
GO:0046627;negative regulation of insulin receptor signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.517298617381897;294.34753946768484;6.311337724880743;0.009851547250396369;0.6736814700148209;[PID1, TSC2, SLA2, PTPRE, IL1B]
GO:0006729;tetrahydrobiopterin biosynthetic process;8.0;1.0;0.875;9.628524252492122;752.8847007962319;7.8311634786251565;0.02519837338340958;0.7754860644832351;[GCH1]
GO:0051770;positive regulation of nitric-oxide synthase biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;147.28763043943843;7.069023426578259;0.0049295844405465;0.7124295520356204;[CCL20, LRRK2, FCER2, CCL2, TLR4, TLR2]
GO:0045662;negative regulation of myoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.62387697121986;6.518977089658987;0.0038363580074348307;0.6565011041187423;[TGFB1, DLL1, TNF, CXCL10]
GO:0043242;negative regulation of protein complex disassembly;6.0;0.7248374789738407;0.6855390520770648;8.83001655627435;65.72942481560547;5.572381008289503;0.002199904695936496;0.6080921364962873;[LMOD1, TNF, EPS8, SPTAN1, GSN, CKAP2]
GO:0072573;tolerance induction to lipopolysaccharide;8.0;1.0;0.875;9.628524252492122;353.22117304507054;9.083926447120524;0.011821994783401185;0.839552420951524;[TNFAIP3]
GO:0001836;release of cytochrome c from mitochondria;6.0;1.0;0.8231203125901445;9.628524252492122;22.134985108306864;6.686031174322154;7.408380313817617E-4;0.665044257777226;[BCL2A1, SFN]
GO:0002925;positive regulation of humoral immune response mediated by circulating immunoglobulin;10.0;0.8933024483968273;0.861892236059334;9.592156608321247;508.6670988930833;8.390779266560578;0.01702463002928348;0.8443458537639685;[FCER2, TNF]
GO:2000121;regulation of removal of superoxide radicals;7.0;0.8259837884571596;0.7639112594857803;9.4949928598676;93.21217700056023;7.474488534686424;0.003119727678695759;0.7331650565203278;[GCH1, CD36, TNF]
GO:0071803;positive regulation of podosome assembly;8.0;1.0;0.875;9.628524252492122;306.3544197830862;7.379178354882098;0.01025340672906212;0.7523715242355574;[TNF]
GO:0051897;positive regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;4.7664383335842135;0.007979625599047746;0.6187558780415471;[CD80, TNF, FGF5, TNFSF11, PDGFRB, GAB1, BTC, KIT, CHI3L1, HBEGF, ENG, CD19, CCL19, ICOS, TGFB1, TRAT1, EGF, PTK2, LIN28A, CD28, NOX4, TEK]
GO:0043922;negative regulation by host of viral transcription;11.0;1.0;0.9324289523296623;9.628524252492122;272.3838172918008;7.292166977892469;0.009116441235236167;0.8053507106995271;[CCL5, CCL4]
GO:0045429;positive regulation of nitric oxide biosynthetic process;8.0;1.0;0.875;9.628524252492122;658.6394256443023;6.166155715036245;0.02204406883931546;0.6903374900225189;[PTGS2, TNF, KLRK1, AKT1, CD36, AGXT2, DNM2, IFNG, IL1B, PTX3, TLR4]
GO:0006024;glycosaminoglycan biosynthetic process;6.0;0.7586651285174919;0.7024528768488905;9.158520623246385;237.49504005673018;5.16195311083921;0.007948745259039342;0.5871028347338303;[SDC2, NDST3, ST3GAL6, PDGFRB, HS3ST3B1, IL1B, OGN, SDC1, CSPG4]
GO:0097191;extrinsic apoptotic signaling pathway;6.0;0.8259837884571596;0.7361122068187242;9.223059144383958;51.05903939735586;5.277263957350204;0.0017089000984773794;0.5929998367869052;[FASLG, TNF, IL6R, DCC, TNFRSF1B, IFNG, IL1B, BCL2A1, TGFB1, SORT1, TNFSF12, G0S2, TNFRSF10B, INHBA]
GO:0043123;positive regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.11083947336738;4.629579150867016;0.008002824611389124;0.6117568930727868;[GOLT1B, TNF, AKT1, TNFSF11, F2R, NDFIP2, PLK2, TNFRSF10B, CCDC22, FASLG, NUP62, CD36, ZDHHC17, IL1B, LTF, FLNA, CCL19, CARD9, CD4, LTBR]
GO:1904999;positive regulation of leukocyte adhesion to arterial endothelial cell;8.0;1.0;0.875;9.628524252492122;88.73789627057504;9.777073627680469;0.0029699775292543833;0.875;[TNF]
GO:0038095;Fc-epsilon receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.5544162803384;78.4757768553383;4.989581884898423;0.002626513627734276;0.6301674496329921;[GRAP2, FCER1A, LAT2, BTK, PAK1, IGKC, IGLV1-44, LYN, NFKB1, IGKV3-20, LAT]
GO:0045665;negative regulation of neuron differentiation;8.0;0.6162540371078848;0.6831270185539424;8.732436227935485;338.1488864638422;4.401795219996305;0.011317538915704735;0.6001080122550225;[SEMA5B, EDNRB, TNR, PAQR3, JAG1, PLK2, PTK2, ITM2C, NRP1, LRRK2, DCC, RGMA, IL1B, NLGN1, LRP1, DLL1, LINGO1, SEMA4B, MEIS1]
GO:0043243;positive regulation of protein complex disassembly;6.0;0.7192862368539868;0.682763431017138;8.781226392104918;65.71852696664936;6.250713103064308;0.002199539954739362;0.6427820713687392;[ADRB2, TNF]
GO:0097192;extrinsic apoptotic signaling pathway in absence of ligand;7.0;1.0;0.8509193652572005;9.628524252492122;76.30875120206336;6.375876246018314;0.0025539852293156346;0.6769819729871445;[BCL2A1, DCC, IL1B]
GO:0043124;negative regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.487551390376;6.063501560976162;0.008015432820232688;0.6850877518099798;[TNFAIP3, PYCARD, NLRP12, CCDC22]
GO:0045668;negative regulation of osteoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.56398573135455;170.3268387162597;6.015873511986907;0.0057006860076304205;0.6307723637598831;[TMEM64, TNF, MEN1]
GO:0002223;stimulatory C-type lectin receptor signaling pathway;11.0;1.0;0.9324289523296623;9.628524252492122;628.1099736002739;5.618190544320798;0.02102227555412486;0.7197434780388068;[ICAM2, PAK1, KLRK1, MUC15, LYN, CARD9, NFKB1, CLEC4D]
GO:0032308;positive regulation of prostaglandin secretion;10.0;0.8933024483968273;0.861892236059334;9.548481544818586;484.66648287468473;7.474488534686424;0.016221351010299763;0.7974867031240476;[IL1B, TNFSF11, TNFRSF11A, MIF]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[IL5RA, TNF, FGF5, TNFSF11, MEN1, PDGFRB, MEF2C, MAP2K2, PAQR3, BTC, CSF2RB, IQGAP3, RASGRP4, TGFB1, PTK2, NFKB1, LAT, LRRK2, CCR5, SPTAN1, MAP4K1, DUSP6, IL1B, KIT, HBEGF, CCL5, CCL2, NCAM1, EGF, IL2RB, TEK]
GO:0043491;protein kinase B signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;6.250713103064308;8.845336528452411E-4;0.6427820713687392;[TGFB1, TSC2, TNF, PAX2, TMEM100, CCL5, IL1B, AKT1, CCL2]
GO:0045672;positive regulation of osteoclast differentiation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;840.7838216260375;6.599019797332524;0.0281402778535103;0.7337148045016781;[CCR1, TMEM64, TNF, IFNG, TNFSF11, IL17A]
GO:0051781;positive regulation of cell division;5.0;0.6763753087927167;0.6284286662572787;8.438940185618286;42.28939918509474;5.358233019883872;0.0014153881327367882;0.5642612976810992;[CXCR5, TGFA, FGF5, RACGAP1, PDGFD, NUP62, PDGFC, SVIL, TGFB1, TAS2R13, CDC6, PPBP, CIT, BTC, IL1B]
GO:0071398;cellular response to fatty acid;6.0;0.7369933605727446;0.6916169928765168;9.004369943419128;203.00017448222317;5.8067817141283475;0.006794233151624104;0.6200793994936333;[PID1, PTGER2, PTAFR, P2RY6, AKT1, FFAR2, PTGDR, DGAT2, IL1B]
GO:0001922;B-1 B cell homeostasis;8.0;1.0;0.875;9.628524252492122;22.00128503895464;8.67846133901236;7.363632103827933E-4;0.8188169164668168;[TNFAIP3]
GO:0050691;regulation of defense response to virus by host;7.0;0.8933024483968273;0.7975705894556142;9.474373572664863;72.38922322033065;6.166155715036245;0.0024228021551132095;0.6662568552797195;[TNFAIP3, LILRB1, MMP12, IL1B]
GO:0010875;positive regulation of cholesterol efflux;9.0;1.0;0.896240625180289;9.628524252492122;184.0088741739662;7.069023426578259;0.0061586114213673755;0.757750811958709;[ABCA1, NFKBIA, LRP1, NR1H2]
GO:2001240;negative regulation of extrinsic apoptotic signaling pathway in absence of ligand;10.0;1.0;0.9152410118609203;9.628524252492122;570.2036429558796;6.221725566191056;0.019084202779771145;0.7334203466557586;[CX3CR1, TNF, IL1B, AKT1, PF4]
GO:0071947;protein deubiquitination involved in ubiquitin-dependent protein catabolic process;10.0;1.0;0.9152410118609203;9.628524252492122;256.8414417838795;7.9853141584524145;0.008596251914215869;0.8236103492792612;[TNFAIP3]
GO:0033198;response to ATP;6.0;0.9326813400603323;0.7894609826203107;9.56398573135455;115.93137747960115;6.375876246018314;0.0038801188727762915;0.6491829203200885;[TRPC3, PTGS2, SLC8A1, P2RX5, P2RX1, IL1B]
GO:0007249;I-kappaB kinase/NF-kappaB signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;5.602686357784832;8.845336528452411E-4;0.6096419534788213;[TNF, AKT1, BTK, TLR8, TLR7, TLR4, LY96, CARD9, NFKB1, NFKBIA]
GO:0071260;cellular response to mechanical stimulus;5.0;1.0;0.7902410118609202;9.628524252492122;56.1235610070294;5.420364800990877;0.00187840507897962;0.5674387198563348;[CHEK1, AKT1, IL1B, TLR8, TLR7, TLR5, TLR4, ENG, PTGS2, TGFB1, TNFSF14, TNFRSF10B, NFKB1, LTBR]
GO:2001236;regulation of extrinsic apoptotic signaling pathway;8.0;0.7436939687323844;0.7468469843661922;9.280217558223907;63.25132987212929;4.74012102526684;0.002116965088319004;0.6174100096703167;[TNF, PYCARD, LGALS3, PPP2R1A, AKT1, MAL, ATF3, TNFSF12, CAV1, TNFRSF10B, INHBA, ITM2C, NRP1, HMGB2, TNFAIP3, FASLG, TRAF1, IL1B, CX3CR1, G0S2, PPP1CA, LTBR, PF4]
GO:0030593;neutrophil chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;130.2972973825895;5.382624473008031;0.004360933283440787;0.671508291047556;[CXCL6, CCL13, CXCL9, CSF3R, C5AR1, CXCL1, CXCL13, CXCL3, CXCL2, CXCL5, LGALS3, CCL8, CXCR1, CCL7, CCL5, CXCR2, CCL4, PDE4B, CCL2, CCL1, CCL19, CCL18, CCL23, CXADR, CCL20, PPBP, CXCL10, CXCL11, IL1B, XCL1, S100A8, PF4]
GO:2001238;positive regulation of extrinsic apoptotic signaling pathway;9.0;0.8653626801206646;0.8289219652406215;9.54514264355307;358.11284317915005;5.8650506222523235;0.011985714580571521;0.6961795867550195;[PYCARD, PPP2R1A, TNFSF12, CAV1, G0S2, INHBA, PPP1CA, MAL, LTBR, ATF3, ITM2C]
GO:0001937;negative regulation of endothelial cell proliferation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;87.36028873802138;6.193554689224359;0.002923870244906099;0.6676580400938822;[MEF2C, CAV2, CAV1, PRL, TNF, CCL2]
GO:0010888;negative regulation of lipid storage;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;46.28121162512291;6.8867018697843045;0.001548990502706573;0.6753065664753021;[ABCA1, NR1H2, TNF, NFKBIA]
GO:0051798;positive regulation of hair follicle development;6.0;0.8259837884571596;0.7361122068187242;9.377209824211215;137.70877785042182;7.292166977892469;0.004608988864799761;0.6960420709600095;[TNF]
GO:0010884;positive regulation of lipid storage;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;46.19953359410991;6.686031174322154;0.0015462568125140237;0.665044257777226;[MSR1, NR1H2, NFKB1, CD36]
GO:0010460;positive regulation of heart rate;8.0;0.7763722522362496;0.7631861261181248;9.249034630787218;94.35920462208708;6.641579411751319;0.003158117660930423;0.7146506799819907;[GCH1, KCNQ1, TPM1, TACR3, AVPR1A]
GO:0032495;response to muramyl dipeptide;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;59.66765988983927;7.004484905440688;0.0019970228791053504;0.6813299963962409;[JAG1, CARD9, TNFAIP3, NFKBIA]
GO:0051291;protein heterooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;5.113634533568402;0.00140677858073304;0.5846318204451575;[NUP62, MCCC2, CHRNB4, CLDN3, NUP54, NLGN1, JUP, GCH1, P2RX1]
GO:0045840;positive regulation of mitotic nuclear division;8.0;0.7140352122741334;0.7320176061370667;9.138976027173417;276.06341799230654;5.75172193694532;0.009239594159256459;0.6691433273378073;[TGFA, PHB2, NUP62, SH2B1, PDGFRB, RANBP2, RANBP1, TGFB1, EGF, BTC, IL1B, CD28]
GO:0043547;positive regulation of GTPase activity;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;49.33745512692421;3.758480413184235;0.001651280222271285;0.5153291757075998;[RACGAP1, EZH2, DENND1B, NRP1, ARHGAP6, RHOG, CCL13, CCL19, CCL18, RANBP2, RANBP1, CCL23, CCL20, SIPA1, CXCL13, RGS1, F2R, TSC2, ACAP1, PRTN3, ADAP2, EVI5, CAV2, TBCK, LRRK2, TBC1D9, ARAP3, ALDH1A1, XCL1, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1]
GO:0030866;cortical actin cytoskeleton organization;6.0;0.7671156992804218;0.7066781622303554;9.117698628726131;53.946853691669205;6.088194173566533;0.0018055526440439148;0.63447084575632;[TNF, RACGAP1, TLN1]
GO:0002711;positive regulation of T cell mediated immunity;8.0;0.7436939687323844;0.7468469843661922;9.271849308553389;266.2800456662771;5.9928839937622085;0.008912153491967712;0.6814763661386056;[CD1E, CD1B, CD1A, HSPD1, NLRP3, FZD5, IL1B, XCL1]
GO:0048566;embryonic digestive tract development;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;33.609109414970646;7.004484905440688;0.001124866645884346;0.6484506956670166;[TNF]
GO:0051044;positive regulation of membrane protein ectodomain proteolysis;9.0;1.0;0.896240625180289;9.628524252492122;964.0127980139503;7.069023426578259;0.03226464079433516;0.757750811958709;[IFNG, IL1B, ADAM9, TNFRSF1B, TNF]
GO:0071333;cellular response to glucose stimulus;8.0;1.0;0.875;9.628524252492122;272.3004295980195;5.69953618377475;0.009113650324169357;0.6664745454937787;[MEN1, PAX2, LIN28A, IL1B, NOX4]
GO:0035998;7,8-dihydroneopterin 3'-triphosphate biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;579.5780854622164;9.777073627680469;0.019397956934007726;0.8231203125901445;[GCH1]
GO:0072666;establishment of protein localization to vacuole;7.0;0.7980440201809971;0.7499413753476991;9.34084218004034;89.19876255650254;6.039404009397101;0.0029854023090916475;0.6597747671587765;[SCARB2, TNFAIP3, LAMP2, HGS, VPS41]
GO:0050999;regulation of nitric-oxide synthase activity;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;24.724602712185703;6.039404009397101;8.275102020790521E-4;0.6319757144917204;[CNR1, AKT1, GCH1, CAV1, DNM2, FCER2, IL1B]
GO:0033574;response to testosterone;5.0;0.9326813400603323;0.7565816818910864;9.533214072687796;91.03892825708995;6.063501560976162;0.003046990999048697;0.6003287636709002;[PLN, DUSP1, NASP]
GO:0031397;negative regulation of protein ubiquitination;10.0;0.7508913569872202;0.7906866903545304;9.372590878354922;529.4632463014641;5.572381008289503;0.01772065836772442;0.7002128357670632;[TNFAIP3, AKT1, FBXO5, CAV1]
GO:2001243;negative regulation of intrinsic apoptotic signaling pathway;9.0;0.7436939687323844;0.7680876095464813;9.413412872875176;597.3701724921605;5.233778845410465;0.0199934420750612;0.663896318730187;[LRRK2, AKT1, MIF, MMP9, NDUFS3, BCL2A1, PTGS2, FIGNL1, WFS1, VNN1, CXCL12, GRINA]
GO:0032800;receptor biosynthetic process;6.0;0.8259837884571596;0.7361122068187242;9.318369324188282;73.9644013438808;8.16763571524637;0.002475521949340158;0.7408135829017477;[TNF]
GO:0050995;negative regulation of lipid catabolic process;7.0;0.7671156992804218;0.7344772148974115;9.0689084645567;114.83297947662612;6.686031174322154;0.003843356480110741;0.692843310444282;[CNR1, IL1B, AKT1, TNF]
GO:2000279;negative regulation of DNA biosynthetic process;8.0;0.7980440201809971;0.7740220100904985;9.434368238051164;829.3243434921358;6.166155715036245;0.02775673943322936;0.6903374900225189;[DUSP1, DACH1, MEN1]
GO:0010575;positive regulation of vascular endothelial growth factor production;6.0;1.0;0.8231203125901445;9.628524252492122;64.54350789155374;6.481236761676141;0.002160213123744424;0.6545710619905948;[TGFB1, C5AR1, PTGS2, SULF2, IL1B, C3AR1]
GO:0050996;positive regulation of lipid catabolic process;7.0;0.7248374789738407;0.7133381047441208;8.85533436425864;114.22740612088849;6.641579411751319;0.0038230884848748396;0.6905700452391912;[IL1B]
GO:0032480;negative regulation of type I interferon production;6.0;0.7980440201809971;0.722142322680643;9.186691500213083;65.25422870398782;6.015873511986907;0.002184000309729388;0.6307723637598831;[TNFAIP3, PYCARD, HAVCR2, LILRB1]
GO:1904385;cellular response to angiotensin;8.0;1.0;0.875;9.628524252492122;462.69925393661634;7.379178354882098;0.015486127626965131;0.7523715242355574;[CDC6, SLC30A10, NFKB1]
GO:0035871;protein K11-linked deubiquitination;10.0;1.0;0.9152410118609203;9.628524252492122;204.99431233642397;7.474488534686424;0.006860975150996652;0.7974867031240476;[TNFAIP3]
GO:0046827;positive regulation of protein export from nucleus;9.0;0.811012628672052;0.801746939516315;9.431813958246067;516.7269860224134;6.7325511899570465;0.017294387198074676;0.740543606130341;[IL1B, SFN]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[MRGPRF, EDNRB, GPR171, C3AR1, AKT1, PROK2, PTGDR, TAS2R10, TAS2R13, TAAR2, TRHR, ADCY9, AGTR1, FPR1, FPR3, FPR2, CCR10, CCR1, ABCA1, GPR15, FZD5, OR2J2, AZU1, NMBR, PPBP, MARCO, PNOC, GPR18, GPR19, GPR25, GABRB1, CD3E, CCR9, FFAR2, CCR6, CCR5, CCR2, GPR37, ANXA1, RHOG, GPBAR1, TACR3, AGTRAP, PTH2R, AVPR1A, SORCS3, MC3R, CCL13, PTGER2, PTAFR, CXCR5, CXCR4, CXCR6, GNAI1, GNAI2, FGD4, CXCR1, CXCR2, FLNA, CCL19, GABRE, CCL18, GPR157, P2RY13, GABBR1, CCL23, SORT1, GABRA5, CCL20, P2RY14, GPR6, RAMP1, LGR4, F2RL3, PF4, CHRM2, CHRM1, CELSR1, CXCL13, CXCL16, RGS1, CCRL2, PDGFRB, CD97, GHSR, LHCGR, F2R, NPY1R, DGKZ, SPNS1, SUCNR1, CALCRL, GPR87, C5AR1, GPR85, GPR84, ADRB2, GPR82, HRH4, DRD4, HTR1E, CAV1, GPR98, CXCL10, CXCL11, CXCL12, GNB2, TAS2R7, CXCL6, CXCL9, OR1G1, CXCL1, CXCL3, CXCL2, CXCL5, GRM5, PDE4B, PTGIR, GLP2R, XCL1, CX3CR1, LRP1, OR1E1, P2RY6, CCL8, PLN, CCL7, CNR1, P2RY2, OR2W1, CCL5, CCL4, CCL2, S1PR3, OR12D3, CCL1, S1PR5, TSHR, OR11A1]
GO:1901671;positive regulation of superoxide dismutase activity;9.0;1.0;0.896240625180289;9.628524252492122;578.3848868100486;8.67846133901236;0.019358021648928737;0.8400575416471059;[TNF]
GO:0032481;positive regulation of type I interferon production;6.0;0.811012628672052;0.7286266269261705;9.260799472366804;65.23665507211369;5.618190544320798;0.002183412136085803;0.610434838299289;[HMGB2, MMP12, TLR8, TLR7, TLR4, TLR2, HSPD1, NFKB1]
GO:2000173;negative regulation of branching morphogenesis of a nerve;7.0;1.0;0.8509193652572005;9.628524252492122;148.90868040495974;9.777073627680469;0.0049838395240422466;0.8509193652572005;[IL1B]
GO:0060559;positive regulation of calcidiol 1-monooxygenase activity;10.0;1.0;0.9152410118609203;9.628524252492122;1344.9571378328073;8.67846133901236;0.04501450502042472;0.8590579283277371;[IFNG, IL1B, TNF]
GO:0043312;neutrophil degranulation;9.0;1.0;0.896240625180289;9.628524252492122;132.80263134205524;3.603287523778533;0.004444784556409926;0.5805129167163294;[CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, NFAM1, SERPINB10, PTAFR, ALOX5, GSN, LRG1, SLCO4C1, SIGLEC5, HP, APEH, PYCARD, CLEC5A, LAMP2, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, BRI3, HVCN1, GPR84, ATP8B4, DEFA4, DEFA1, NFKB1, LCN2, ITGAM, FCAR, FCGR3B, CR1, NDUFC2, TNFRSF1B, PECAM1, BPI, ACPP, TTR, FCGR2A, P2RX1, FOLR3, LGALS3, ANPEP, SLC11A1, MIF, CHIT1, SLPI, CRISPLD2, STXBP2, MGST1, PRG2, NBEAL2, PPBP, BST1, VNN1, ORM1, CTSS, GLIPR1, CTSG, CD36, SPTAN1, CAMP, CD33, CCT2, MME, RHOG, CEACAM1, CEACAM6, TLR2, LILRA3, CXCR1, CXCR2, CD58, CCT8, LILRB2, LILRB3, QPCT, CD68, CD97, CHRNB4, CD93, OSCAR, DOK3, PRTN3, VCL, C5AR1, MGAM, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, MMP9, CHI3L1, LTF, CLEC12A, RETN, S100P, PTX3]
GO:0045736;negative regulation of cyclin-dependent protein serine/threonine kinase activity;12.0;0.8933024483968273;0.8947715367885583;9.585964638073326;2927.1185870500644;6.375876246018314;0.09796802487286638;0.7741829203200885;[CDKN1A, MYOCD, CDKN2C, TNFAIP3, HHEX, MEN1]
GO:0043434;response to peptide hormone;6.0;0.6696747006330769;0.657957662906683;8.712233520617966;71.32532737153224;4.149452513989832;0.0023871945184980284;0.5353235071248601;[CYFIP1, CTGF, EDNRB, AKT1, MEN1, GHSR, LHCGR, POR, ADCY9, ABCB4, SLC30A10, FOXO1, PRKAR2B, LYN, EGR1, EGR2, EIF2B3, TGFB1, CAV1, CDC6, NFKB1, NR4A2, NR4A1, CXCL12, HHEX, ANXA1, ARG1, GLP2R, TGFBR3, CEACAM1, IL1B, TLR2, RETN, PTGS2, GNAI1, PAK1, PLN, SORT1, SORBS1, TSHR, TEK]
GO:0033209;tumor necrosis factor-mediated signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;30.19135422731818;5.395046993006588;0.00101047745553359;0.6268223193749;[TNFRSF13B, TNF, TNFSF13B, PYCARD, TNFSF11, TNFRSF1B, TNFRSF11A, TNFRSF17, TNFSF14, TNFSF12, TNFRSF10C, TNFRSF10B, NFKBIA, LTBR]
GO:0035509;negative regulation of myosin-light-chain-phosphatase activity;11.0;1.0;0.9324289523296623;9.628524252492122;1252.1557676251311;8.16763571524637;0.04190852667538468;0.8501222226412654;[TNF]
GO:0032355;response to estradiol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;74.25476231829794;4.940791720728991;0.0024852400698459885;0.542913330229313;[BRCA2, CTGF, PDGFRB, GHSR, ANXA1, DUSP1, TACR3, IL1B, PCNA, ABCB4, PTGS2, RBBP8, TGFB1, GH1, CD4, EZH2]
GO:0035505;positive regulation of myosin light chain kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1426.5997261217476;9.777073627680469;0.0477470089768964;0.9481203125901445;[IL1B]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[CXCL13, TNF, CTGF, CXCL16, FGF5, VSTM1, TNFSF11, MEF2C, IFNA14, IFNA16, FLT3LG, MIF, BTC, IFNA10, TGFA, ADRB2, PDGFD, PDGFC, IFNA21, TGFB1, JAG1, TNFSF14, TNFSF12, INHBA, PPBP, GH1, CXCL10, CXCL11, CXCL12, PNOC, OGN, CD320, IFNA5, IFNA4, NRP1, CXCL6, IFNA7, CXCL9, IFNA2, CXCL1, FASLG, PRL, CXCL3, IFNA8, CXCL2, CXCL5, TNFSF13B, IFNG, IL1B, XCL1, HBEGF, CCL13, NLGN1, CLEC12B, RETN, CCL8, TTR, GPNMB, CCL7, CCL5, CCL4, CCL2, CCL1, CCL19, CCL18, CCL23, EGF, CCL20, CMTM2, FCGR2B, PF4, IL17A]
GO:0030177;positive regulation of Wnt signaling pathway;7.0;0.7307253602413294;0.7162820453778652;9.040737587590003;188.4547261984632;4.948759890378168;0.006307410087620234;0.6039991761920099;[LRRK2, TNFAIP3, HHEX, RUVBL1, NAIP, TLR2, JUP, EGF, CAV1, NFKB1, SULF2, LGR4]
GO:0050766;positive regulation of phagocytosis;8.0;0.7671156992804218;0.7585578496402109;9.34084218004034;175.32691305650852;5.825829909099042;0.005868033996023792;0.6729332124801218;[SIRPG, TNF, SIRPB1, PYCARD, STAP1, CCL2, CD36, SLC11A1, AZU1, DNM2, IL1B, PTX3, FCGR2B]
GO:0072659;protein localization to plasma membrane;6.0;0.7866048967936545;0.7164227609869718;9.260799472366804;65.42666064804821;4.677207199856271;0.002189771451718415;0.5623129063031725;[TNF, CDH1, GOLPH3L, ATP1B1, TSPAN33, FLNA, TSPAN5, JUP, RAMP1]
GO:0035066;positive regulation of histone acetylation;11.0;0.811012628672052;0.8379352666656883;9.498471124243924;1302.9179711131005;6.444869117505266;0.043607491943109866;0.7620198587159455;[TGFB1, IL1B]
GO:0045746;negative regulation of Notch signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;188.1075192762445;6.193554689224359;0.006295789384399518;0.6676580400938822;[EGF, NFKBIA, BCL6]
GO:0070262;peptidyl-serine dephosphorylation;8.0;1.0;0.875;9.628524252492122;179.24922260518233;7.292166977892469;0.005999310166768488;0.747921758369865;[PPP2R1A, DUSP1, PPP1CA]
GO:0071230;cellular response to amino acid stimulus;6.0;0.7140352122741334;0.6801379187272112;8.962045319014338;283.89643900763554;5.6339389012889365;0.009501758323378283;0.6112402100070131;[ABCB4, TNF, PDGFD, PDGFC]
GO:1904707;positive regulation of vascular smooth muscle cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;80.75549718811011;6.444869117505266;0.0027028138156570515;0.6805102716434839;[MMP9, TNF, GNAI2, PAK1]
GO:0071354;cellular response to interleukin-6;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;7.004484905440688;0.0027327542132076126;0.6813299963962409;[PID1, ST3GAL6, NFKB1]
GO:0043330;response to exogenous dsRNA;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;30.956451235720028;5.970411137910149;0.0010360845638621964;0.6284474158353811;[IFNA5, COLEC12, IFNA4, IFNA7, IFNA14, IFNA16, CAV1, IFNA2, CARD9, IFNA8, NFKBIA, IFNA21, IFNA10]
GO:0071359;cellular response to dsRNA;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;141.5689593603356;6.781341354126479;0.004738185665998763;0.6699184248047958;[COLEC12, CAV1, NFKB1]
GO:2000178;negative regulation of neural precursor cell proliferation;6.0;0.7980440201809971;0.722142322680643;9.117698628726131;64.43316573945785;6.781341354126479;0.002156520071215264;0.6699184248047958;[TGFB1, SPINT1, IL1B, SPINT2]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[PID1, PYCARD, TCL1A, AKT1, CHI3L1, XCL1, CCL13, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, CD58, CCL19, CCL18, CCL23, CCL20, NFKB1]
GO:0071236;cellular response to antibiotic;4.0;0.6369964171292115;0.5684982085646058;7.703233390639544;41.40086873190647;5.085725745451326;0.0013856498180940687;0.5100842511328143;[TNFAIP3, IL18RAP, MYB, MEF2C, ANXA1, ARG1, PAX2, IL1B, PCNA, ABCB4, GNAI1, FOXO1, CCL7, PDGFD, EGR1, EZH2]
GO:0045071;negative regulation of viral genome replication;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;85.23964546052278;5.8067817141283475;0.0028528942228632634;0.6719590869034888;[TNF, CCL5, SLPI, LTF]
GO:0050776;regulation of immune response;4.0;0.37937792944451876;0.4396889647222594;5.635843344046521;22.446924158408432;2.846578861728843;7.512783506617425E-4;0.39557417536826767;[, CYFIP1, TFRC, SLA2, MYB, C3AR1, UBASH3A, MEF2C, CXADR, HHLA2, FPR1, FPR3, FPR2, KLRK1, IGHA1, HLA-DQA1, ELANE, LYN, HLA-DRB4, FZD5, KIR2DS1, KIR2DS2, DENND1B, SIGLEC9, HLA-DPA1, HAVCR2, ANXA1, ARG1, FCRL3, NFAM1, PAWR, SERPINB9, PAX5, MMP12, FCER2, TLR10, HLA-DQB1, PTAFR, UNG, HLA-DMB, CCL19, NR1H2, CARD9, KIR3DL1, HLA-DPB1, PKN1, CLC, LGR4, CXCL13, TNF, PYCARD, IGHG1, FCGRT, GRAP2, IL13RA2, CD177, LAG3, CD180, MSH6, CLEC4D, MSH2, S100A8, BLK, CD274, LY96, IGLV1-44, EIF2B3, BMX, NFKB1, BCL6, HLA-DRA, LAT, ITGAM, TREM2, TREM1, TNFSF13B, FCGR3A, CR2, CR1, PVRIG, XCL1, UNC93B1, NLRC4, CCL5, FCGR1B, FCGR2A, FCGR2B, CLEC2D, ICAM2, LGALS3, ICOSLG, SLC11A1, MIF, BTK, STXBP2, CD1E, CD1B, CD1A, CD79B, CD79A, CD19, SLAMF7, SH2D1A, PTK2, MARCO, CD28, CD24, CD200, IGHM, IFNA2, CD3G, CD3E, CTSS, FCER1A, FFAR2, CTSG, MUC15, CD36, CD33, CCR2, LAT2, TLR1, NCR1, CEACAM1, IL1B, KIT, IGHD, TLR8, TLR7, TLR5, TLR4, TLR2, PAK1, IGKC, NPDC1, LILRB1, LILRB2, MLH1, CD80, IL18RAP, IL6R, OSCAR, KLRF1, CD300C, C5AR1, KIR2DL1, KIR2DL2, KIR2DL3, STAP1, NLRP3, TGFB1, CAV1, NFKBIA, IGKV3-20, HMGB2, TNFAIP3, PDE4B, IFNG, LTF, COLEC12, CLEC12B, SAMHD1, HSPD1, CNR1, TRAT1, CD4]
GO:0060693;regulation of branching involved in salivary gland morphogenesis;6.0;0.8653626801206646;0.7558016526504768;9.36615998802463;93.99544391330774;7.697632086000634;0.0031459429173709623;0.7167775754447168;[TNF]
GO:0035176;social behavior;3.0;1.0;0.6981203125901445;9.628524252492122;22.58175877758554;5.8067817141283475;7.557911440223213E-4;0.49507939949363344;[NLGN4Y, NRXN3, AVPR1A, IL1B, DRD4]
GO:0035970;peptidyl-threonine dephosphorylation;8.0;1.0;0.875;9.628524252492122;179.24922260518233;7.004484905440688;0.005999310166768488;0.7332096838060964;[DUSP1, PPP1CA]
GO:0010693;negative regulation of alkaline phosphatase activity;10.0;1.0;0.9152410118609203;9.628524252492122;315.7238800504293;8.67846133901236;0.010566994132243301;0.8590579283277371;[TNF]
GO:0045638;negative regulation of myeloid cell differentiation;7.0;0.7307253602413294;0.7162820453778652;9.186691500213083;279.0827475916144;5.4730085344763;0.00934064840372507;0.6308092762312435;[HOXA9, GPR171, HOXA7, HOXA5, CEACAM1, TLR4, LTF, DLL1, LYN, LILRB1, INHBA, LILRB3, MEIS2, NFKBIA, MEIS1, PF4]
GO:0070936;protein K48-linked ubiquitination;11.0;1.0;0.9324289523296623;9.628524252492122;157.60047254366168;5.8650506222523235;0.00527474598481953;0.7323679139043926;[TNFAIP3, HACE1]
GO:0006198;cAMP catabolic process;11.0;1.0;0.9324289523296623;9.628524252492122;5918.161003974418;7.138016298065211;0.19807552280391336;0.7974674377644215;[PDE4B]
GO:0045994;positive regulation of translational initiation by iron;10.0;1.0;0.9152410118609203;9.628524252492122;1474.0558344206913;9.083926447120524;0.049335322213937396;0.8797934328124444;[TNF]
GO:1900127;positive regulation of hyaluronan biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;589.7686013946351;8.390779266560578;0.019739024331396862;0.8253454670833372;[EGF, NFKB1]
GO:0045086;positive regulation of interleukin-2 biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.8798377098682;7.292166977892469;0.027942676825076673;0.747921758369865;[CD4, CD80, IL1B, CD28, CD3E]
GO:0045083;negative regulation of interleukin-12 biosynthetic process;8.0;1.0;0.875;9.628524252492122;836.0204953067102;9.777073627680469;0.027980853608317785;0.875;[NFKB1]
GO:0071222;cellular response to lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;237.99812851129587;4.786641040901733;0.007965583176863442;0.5679093580234316;[CXCL6, CXCL9, CD80, HMGB2, TNFAIP3, CXCL1, CXCL13, CXCL3, CXCL2, CXCL5, PYCARD, EDNRB, PDE4B, CTSG, CD36, CCR5, HAVCR2, GHSR, MEF2C, ARG1, CD180, PDCD1LG2, TNFRSF1B, IL1B, ADAM9, TLR4, CX3CR1, CD274, CEBPE, KLRK1, STAP1, NLRP3, CCL2, ABCA1, CCL20, NR1H2, DEFA4, LILRB1, DEFA1, LILRB2, PPBP, NFKB1, CXCL10, CXCL11, PF4]
GO:2000866;positive regulation of estradiol secretion;9.0;1.0;0.896240625180289;9.628524252492122;439.69537685412286;8.67846133901236;0.014716208563159352;0.8400575416471059;[IL1B]
GO:2000503;positive regulation of natural killer cell chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;1000.5321764499969;7.9853141584524145;0.03348691152528284;0.8407982897480031;[CCL7, CCL5, CCL4, XCL1]
GO:0071223;cellular response to lipoteichoic acid;6.0;1.0;0.8231203125901445;9.628524252492122;155.87545856417063;7.474488534686424;0.005217011319337755;0.7053660038532718;[CCL20, TREM2, CD36, TLR2]
GO:0070373;negative regulation of ERK1 and ERK2 cascade;11.0;1.0;0.9324289523296623;9.628524252492122;1180.902522994834;5.6339389012889365;0.039523744701365535;0.7205488497465309;[PTPRR, LYN, DUSP1, DUSP6, NLRP12, TLR4, ATF3]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[, SLA2, LGALS3, RNASE6, RNASE3, MIF, SLPI, BTK, PADI4, NAIP, LY9, KLRK1, SLAMF7, IGHA1, LYN, KIR2DS1, KIR2DS2, SH2D1A, KIR2DS4, KIR2DS5, PTK2, MARCO, VNN1, IFNA5, IFNA4, IGHM, IFNA7, IFNA2, IFNA8, CAMP, HAVCR2, ANXA1, ARG1, TLR1, IGHD, TLR8, TLR10, TLR7, TLR5, TLR4, TLR2, LILRA5, IGKC, CARD9, KIR3DL1, LGR4, PYCARD, IGHG1, GRAP2, CLEC5A, CD177, IFNA14, IFNA16, CD180, CLEC4D, S100A8, IFNA10, BLK, LY96, CORO1A, NLRP3, IFNA21, TGFB1, DEFA4, DEFA1, BMX, NFKB1, LCN2, ITGAM, CRISP3, HMGB2, TREM2, TREM1, SIRPB1, CR2, CR1, LTF, COLEC12, UNC93B1, HIST1H2BK, NLRC4, CD6, PTX3]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[PHB2, TNF, CTGF, PYCARD, TNFSF11, EPHB1, PDGFRB, F2R, MIF, EPHA3, C5AR1, FPR2, TNFRSF11A, SLC30A10, PDGFD, PDGFC, CCR1, TGFB1, MARCO, NOX4, NRP1, TREM2, CD36, HAVCR2, IL1B, KIT, CHI3L1, XCL1, CCL13, GNAI2, CCL8, GPNMB, CCL7, CCL5, CCL4, CCL2, CCL1, CCL19, CCL18, CCL23, CCL20, TIE1, CD4, TEK]
GO:0071347;cellular response to interleukin-1;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.446340287394138;0.0027327542132076126;0.6016464081682054;[CCL13, PYCARD, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, CCL19, CCL18, CCL23, CCL20, KMO, NFKB1, CHI3L1, XCL1, RBMX, IL17A]
GO:0072679;thymocyte migration;8.0;0.8933024483968273;0.8216512241984136;9.533214072687796;31.84507234699532;9.083926447120524;0.0010658259127495017;0.839552420951524;[CCL20, CCR6]
GO:0070498;interleukin-1-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.845247994956144;0.00101047745553359;0.6498456195510879;[EGR1, IL1R1, IL1R2, NFKB1, NFKBIA, IL1B]
GO:0071346;cellular response to interferon-gamma;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.266214121163619;0.0027327542132076126;0.5924347476504533;[HLA-DPA1, KIF16B, XCL1, TLR4, TLR2, CCL13, STXBP2, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, CD58, CCL19, CCL18, CCL23, GSN, CCL20, ZYX]
GO:0030036;actin cytoskeleton organization;5.0;0.6347111282356054;0.607596575978723;8.048073876931273;29.6146440060229;3.9779809732199434;9.911754834323397E-4;0.49367514382642164;[TNF, MYOZ2, PDGFRB, GAS2L3, CXADR, TPM1, TLN1, PFN1, CORO1A, RACGAP1, MYH11, CORO2A, TBCK, BCL6, NRP1, LMOD1, ARHGEF10L, CXCL1, ANXA1, RHOG, GAB1, PALLD, KIT, RHOU, FGD4, PAK1, FLNA, SORBS1, KRT19, ZYX]
GO:0071108;protein K48-linked deubiquitination;10.0;1.0;0.9152410118609203;9.628524252492122;204.99431233642397;6.375876246018314;0.006860975150996652;0.7413036195908642;[TNFAIP3]
GO:0045080;positive regulation of chemokine biosynthetic process;8.0;0.9326813400603323;0.8413406700301662;9.597752593825367;840.1940438043877;7.697632086000634;0.02812053852058526;0.7686572628545723;[EGR1, IL1B, AZU1, TNF]
GO:0042416;dopamine biosynthetic process;8.0;0.9326813400603323;0.8413406700301662;9.590783924509275;507.8534772351106;7.474488534686424;0.01699739884460309;0.7572456912631272;[NR4A2, GPR37, GCH1]
GO:0043507;positive regulation of JUN kinase activity;13.0;0.8653626801206646;0.8952363048279688;9.582714716460828;4931.413721535565;5.459585514144159;0.16504997927558432;0.7417584218576596;[TNF, TNFSF11, MAP4K1, IL1B, TNFRSF11A, PAK1, CCL19, FZD5, PKN1]
GO:1903364;positive regulation of cellular protein catabolic process;8.0;0.7248374789738407;0.7374187394869203;9.303101852057495;870.9707591387623;4.821246570079209;0.029150607485581233;0.6215587738047448;[AKT1, OSBPL7, PLK2, CAV1, PTK2, CCDC22, LRRK2, TNFAIP3, LRP1, LRP2, EGF]
GO:0051928;positive regulation of calcium ion transport;8.0;0.7043150770688792;0.7271575385344395;8.848365694942547;69.31158403183679;5.085725745451326;0.002319796341169766;0.6350842511328143;[CXCL9, MYLK, LGALS3, PDGFRB, TRPC3, TRPC1, F2R, ATP1B1, XCL1, KCNE3, CD19, CCL5, CCL4, CCL2, CCR1, WFS1, CAV1, CXCL10, P2RX5, CD4, CXCL11, CXCL12, F2RL3]
GO:0008625;extrinsic apoptotic signaling pathway via death domain receptors;7.0;0.9326813400603323;0.8172600352873667;9.523163736834295;52.44533375847466;6.311337724880743;0.0017552981231601008;0.6736814700148209;[FASLG, TNF, SORT1, TNFRSF10B]
GO:0090291;negative regulation of osteoclast proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;83.65590509736859;9.083926447120524;0.0027998878581822827;0.8154717862087246;[TNFAIP3]
GO:0002634;regulation of germinal center formation;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;44.47967864407596;7.57984905034425;0.0014886948151053528;0.738553198190834;[MEF2C, BCL6, TNFAIP3, PKN1, TNFSF13B]
GO:0002876;positive regulation of chronic inflammatory response to antigenic stimulus;9.0;1.0;0.896240625180289;9.628524252492122;533.6829535102606;9.083926447120524;0.01786188817051291;0.8607930461318132;[TNF]
GO:0032725;positive regulation of granulocyte macrophage colony-stimulating factor production;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;64.94897299966192;7.212124270218933;0.0021737836760178982;0.6919486831672181;[CD80, IL1B]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[PHB2, SLC8A1, MYB, AKT1, ACTN4, ATP1B1, CLDN3, ABCB4, PSEN2, EGR1, TGFB1, CAV1, NR4A2, CXCL12, NOX4, CD24, MYOCD, KCND2, AGTRAP, TGFBR3, IL1B, TLR2, CXCR4, PTGS2, PAK1, TEK]
GO:0051000;positive regulation of nitric-oxide synthase activity;7.0;1.0;0.8509193652572005;9.628524252492122;123.23454311126406;6.832634648514029;0.0041245492540456985;0.7003406189322132;[FCER2, GCH1, AKT1]
GO:0032729;positive regulation of interferon-gamma production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;5.6339389012889365;0.002183412136085803;0.6112402100070131;[CD3E, TNF, PYCARD, PDE4B, IL6R, CCR2, HLA-DPA1, HAVCR2, SLC11A1, IL1B, TLR8, TLR7, TLR4, HSPD1, KLRK1, IL12RB2, FZD5, CD2, HLA-DPB1, IL18R1]
GO:0050715;positive regulation of cytokine secretion;9.0;0.6913464685778243;0.7419138594692012;9.0689084645567;549.4808578036607;5.03214149931722;0.0183906298100222;0.6535845754738829;[ORM1, LRRK2, TNF, PYCARD, CLEC5A, FFAR2, HAVCR2, F2R, MIF, IL17RB, MMP12, TLR1, IL1B, IGHD, TLR8, TLR4, TLR2, CD274, NLRP3, CD58, CCL19, FZD5, CD2, NLRP12, IL17A]
GO:0035556;intracellular signal transduction;5.0;0.5140152493238541;0.5472486365228473;6.9204740513899115;23.17027026302992;2.4005655013542495;7.75488093814194E-4;0.41300604323788886;[AKT1, MEF2C, AGTR1, FPR1, FPR2, IQGAP3, PRKAR2B, SFN, LYN, ABCA1, HACE1, AZU1, ARHGAP6, DUSP1, DUSP6, PTAFR, STAT4, DMD, PKN1, LGR4, CTGF, KCNH1, MSH6, MSH2, BLK, LY96, TNFRSF10B, BMX, CORO2A, NFKB1, LRRK2, TNFRSF1B, CCL5, CCL2, E2F7, SH2B1, IL2RB, TNFSF11, PAQR3, MIF, BTC, BTK, RACGAP1, CCR1, PTK2, RGL4, CD24, RGL1, BRCA2, CCR9, CCR6, CD36, CCR5, SPTAN1, CCR2, LAT2, MC3R, IL1B, KIT, PCNA, GNAI2, PAK1, RAMP1, CD80, CELSR1, CCRL2, PDGFRB, DOK3, PSEN2, RASGRP4, GH1, TNFAIP3, GHR, GRM5, NDUFS4, BCL2A1, EPS8L1, EGF, TEK, CYFIP1, EPS8, STMN1, ADCY9, LGALS12, PLK2, CDKN1A, NFAM1, PAX2, CIT, HBEGF, GSN, CCL20, CARD9, IL5RA, TNF, SLC8A1, FGF5, PYCARD, GRAP2, STK32B, MEN1, LHCGR, MAP2K2, DGKZ, NRBP1, RAB32, MELK, CALCRL, DHCR24, BCL6, CNOT3, CSPG4, LAT, TREM1, CX3CR1, RAB21, PLN, DNAJA3, EDNRB, PPP2R1A, CHEK1, PTGDR, SIK1, TP53BP2, CCR10, PRL, RALGPS2, MAP4K1, RHOG, AVPR1A, RAB33B, TLR8, TLR7, RHOU, SGK1, TLR4, PTGER2, CXCR5, CXCR4, CXCR6, CXCR1, CXCR2, PDPN, MLH1, CAMK4, SIPA1, SIRPG, TSC2, ATP1B1, CSF2RB, ADRB2, TGFB1, SELE, NFKBIA, JMY, DOCK5, MCTP1, CXCL1, TMEM100, BLNK, PTGIR, TGFBR3, NCAM1, TSHR]
GO:0032720;negative regulation of tumor necrosis factor production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;85.92712208559752;5.926926025970411;0.002875903446815721;0.6540226378555745;[ORM1, TNFAIP3, GPNMB, HAVCR2, GHSR, LILRB1, BPI, TLR4, GPR18]
GO:0050830;defense response to Gram-positive bacterium;7.0;1.0;0.8509193652572005;9.628524252492122;71.44439831434403;5.334422371190153;0.0023911797157970473;0.6237219733958743;[SEH1L, HIST1H2BK, C5AR1, HMGB2, TNF, KLRK1, NLRP3, CD36, CAMP, HAVCR2, DEFA4, CARD9, RNASE6, RNASE3, DEFA1, LYZ, TLR2]
GO:0033138;positive regulation of peptidyl-serine phosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.59573442966913;778.6672313762616;5.152100814396198;0.026061291479152104;0.6787196871063318;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, TNF, TCL1A, AKT1, IFNA14, IFNA16, MIF, IFNG, IFNA10, PTGS2, PAK1, IFNA21, TGFB1, CAV1]
GO:2000630;positive regulation of miRNA metabolic process;8.0;0.9326813400603323;0.8413406700301662;9.57973408832269;378.4717563008913;8.16763571524637;0.012667109080923946;0.7926932703116032;[NFKB1]
GO:1902042;negative regulation of extrinsic apoptotic signaling pathway via death domain receptors;10.0;0.9326813400603323;0.8815816818910864;9.589303539338841;425.73912115989816;6.193554689224359;0.014249105244888325;0.731979686697602;[HMGB2, TNFAIP3, FASLG, TNFRSF10B]
GO:0061048;negative regulation of branching involved in lung morphogenesis;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;172.0271407751716;9.777073627680469;0.005757593587369696;0.8509193652572005;[TNF]
GO:0050728;negative regulation of inflammatory response;7.0;0.6729672293956388;0.6874029799550199;8.712233520617966;126.17514047852296;5.085725745451326;0.004222968401562039;0.6110036163900148;[TNFAIP6, TNFAIP3, CDH5, GHSR, IL1R2, TNFRSF1B, CALCRL, NT5E, NLRP3, ELANE, NFKB1, NLRP12, TEK, FCGR2B]
GO:0061043;regulation of vascular wound healing;7.0;0.8933024483968273;0.7975705894556142;9.485423408851448;64.5975158839315;8.390779266560578;0.0021620207226452698;0.7800242071602487;[TNFAIP3]
GO:0086004;regulation of cardiac muscle cell contraction;9.0;0.7140352122741334;0.7532582313173557;9.310070521373587;77.56089467992787;6.444869117505266;0.002595893344663791;0.7258315315665724;[PLN, JUP, KCNE3, CAV1, PDE4B, FLNA]
GO:0050729;positive regulation of inflammatory response;7.0;0.657518819034173;0.679678774774287;8.587070377663961;125.85203775116636;4.973052582947213;0.0042121544440509905;0.6052415056197167;[TNF, TNFSF11, FFAR2, CCR2, IL17RB, IL1B, BTK, AGTR1, TLR10, TLR7, TLR4, S100A8, TLR2, SUCNR1, TNFRSF11A, PTGS2, PLA2G7, CNR1, CCL4, CCL18, CCL23, NFKBIA, NLRP12, CD6, CD28, IL17A]
GO:0051260;protein homooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;4.056761851073058;0.00140677858073304;0.5305833023127396;[CDA, KCNG2, TCL1A, TNFSF11, MIF, OLFM4, CLDN3, BLM, MGST1, CD79B, CD79A, NACC2, CAV1, CD3G, CD3E, KCND2, ARG1, NUP54, ACPP, FBP1, COLEC12, NLGN1, HM13, NLRC4, SAMHD1, PLN, GCH1, RAD51, P2RX1, GOPC, RBMX]
GO:0045930;negative regulation of mitotic cell cycle;6.0;0.5833093054345528;0.6147749653074209;7.836764783264067;61.236897459641845;4.271742091748107;0.0020495438483445192;0.5415774018184651;[TNF, CHEK1, KNTC1, MSH6, MSH2, AURKAIP1, BLM, NACC2, SFN, NAE1, TGFB1, PLK2, CDC6, ZWINT, BCL6, CNOT3, EZH2, CDKN1A, TOPBP1, DUSP1, PCNA, GPNMB, CCL2, BUB1, E2F7, WEE1]
GO:0008630;intrinsic apoptotic signaling pathway in response to DNA damage;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;84.23129647150353;5.54296712308321;0.002819145689655962;0.6343869617060081;[CDKN1A, BCL2A1, BRCA2, TNF, PYCARD, SFN, MLH1, TNFRSF1B, MSH6, MSH2]
GO:0042542;response to hydrogen peroxide;5.0;0.9326813400603323;0.7565816818910864;9.541512875502493;79.2907140195247;5.09494240055625;0.0026537888412237636;0.5507966031644187;[HP, TNFAIP3, SLC8A1, IL18RAP, MYB, PDGFRB, ANXA1, DUSP1, ARG1, PAX2, ADAM9, PCNA, FOXO1, PDGFD, SDC1, EZH2]
GO:0061844;antimicrobial humoral immune response mediated by antimicrobial peptide;6.0;1.0;0.8231203125901445;9.628524252492122;44.28377145688295;5.682729065458369;0.0014821379778550245;0.6137353412716126;[CXCL6, CCL13, CXCL9, HIST1H2BK, CXCL1, CXCL13, CXCL3, CXCL2, CXCL5, CAMP, DEFA4, RNASE6, RNASE3, DEFA1, PPBP, CXCL10, CXCL11, LTF, PF4]
GO:0032715;negative regulation of interleukin-6 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;64.96654663153603;6.166155715036245;0.002174371849661483;0.6384578026126634;[ORM1, TNFAIP3, TNF, HAVCR2, GHSR, NLRP12, BANK1, BPI, TLR4]
GO:2000406;positive regulation of T cell migration;10.0;0.7980440201809971;0.8142630219514189;9.461470167828956;351.7821234142529;6.518977089658987;0.011773831087318304;0.7486218033895181;[TNFSF14, CCL20, CXCL13, PYCARD, CXCL10, CXCL12, CCL5, XCL1, CCR2]
GO:0010829;negative regulation of glucose transmembrane transport;7.0;0.8933024483968273;0.7975705894556142;9.533214072687796;65.66986041637082;6.832634648514029;0.002197911129098591;0.7003406189322132;[PID1, IL1B, TNF]
GO:0070431;nucleotide-binding oligomerization domain containing 2 signaling pathway;13.0;1.0;0.9625549647676366;9.628524252492122;488.61025226297863;7.8311634786251565;0.01635334542256394;0.8630410292508717;[NFKBIA]
GO:0050726;positive regulation of interleukin-1 alpha biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;1101.0209221136138;9.777073627680469;0.03685017940864447;0.896240625180289;[CCL20]
GO:0070433;negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;403.9920680879125;8.67846133901236;0.013521250949646067;0.8400575416471059;[TNFAIP3]
GO:0031622;positive regulation of fever generation;9.0;0.8436909121759173;0.8180860812682478;9.454170865347344;276.00155245721845;7.8311634786251565;0.009237523575472428;0.7967266896635242;[CNR1, IL1B, TNFSF11, TNFRSF11A, PTGS2, TNF]
GO:0071407;cellular response to organic cyclic compound;5.0;0.5310727365277519;0.5557773801247963;7.0299582842316;63.0333181336412;3.907776714546695;0.0021096684316296343;0.4900848947730398;[AQP9, AKT1, MEF2C, KCNQ1, ABCB4, ABCA1, EGR1, JUP, NOX4, EZH2, GABRB1, ANXA1, ARG1, IL1B, PTAFR, PTGS2, GNAI1, P2RY13, TNF, SLC8A1, CDH1, BLM, FOXO1, OSBPL7, TGFB1, CAV1, INHBA, NFKB1, NFKBIA, ALPL, SLC26A3, LRRK2, PDE4B, DNM2, COLEC12, P2RY6, CCL5, CCL2, RAD51, KLF5]
GO:0033129;positive regulation of histone phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;1473.5624568792941;7.697632086000634;0.04931880931163779;0.8088982747154926;[IL1B]
GO:0051259;protein complex oligomerization;5.0;0.7763722522362496;0.6784271379790451;9.089527751759436;40.42272244673708;3.6012063575747084;0.0013529121422039536;0.47440687246051283;[CDA, TCL1A, TNFSF11, MCCC2, MIF, CLDN3, MGST1, ACMSD, CD79B, CD79A, JUP, CD3G, CD3E, KCND2, ARG1, GCH1, GOPC, KCNG2, CHRNB4, OLFM4, BLM, NACC2, NLRP3, CAV2, CAV1, TNFAIP3, NUP62, NUP54, ACPP, FBP1, COLEC12, NLGN1, HM13, NLRC4, SAMHD1, PLN, CCL5, RAD51, P2RX1, TEK, RBMX]
GO:0032270;positive regulation of cellular protein metabolic process;7.0;0.47017759384120705;0.586008162177804;7.412950536487706;288.49227156764;2.455885070940991;0.00965557670318086;0.47651344199545814;[, AKT1, AGTR1, FPR1, FPR2, SLC30A10, IQGAP3, PRKAR2B, PDGFD, PDGFC, LYN, AZU1, NOX4, EZH2, GPR37, DUSP6, PTAFR, PTGS2, PKN1, CTGF, IFNA14, IFNA16, S100A8, IFNA10, TNFRSF11A, IFNA21, TNFRSF10B, LRRK2, FASLG, TNFRSF1B, LRP1, LRP2, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, TIE1, EIF3E, FCGR2B, EIF3D, CCNH, TCL1A, TNFSF11, EPHB1, MIF, EPHA3, TGFA, CCR1, EGR1, PTK2, CD28, CD24, NRP1, CD3E, CD36, BANK1, IL1B, KIT, GNAI2, PAK1, NLRP12, RAMP1, CD80, IL6R, PDGFRB, CAV2, CAV1, INHBA, GH1, TNFAIP3, GHR, GRM5, MMP9, PSRC1, CHI3L1, EGF, CD4, TEK, PHB2, MYB, PROK2, ELANE, NDFIP2, ACE, FZD5, PLK2, CDC6, CDKN1A, HAVCR2, FCRL3, HBEGF, ENG, CCL13, GPNMB, CCL19, CCL18, CCL23, GSN, CCL20, NR1H2, CARD9, TNF, PYCARD, MAP2K2, F2R, ADAM9, DRD4, OSBPL7, WFS1, BCL6, CSPG4, CCDC22, LAT, TREM2, CR1, XCL1, NLRC4, RAD50, P2RX1, EDNRB, SKP2, ACSL1, SLC11A1, FLT3LG, AURKAIP1, MARCO, IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, MAP4K1, TLR4, CXCR4, LILRB2, C5AR1, ADRB2, STAP1, NLRP3, TGFB1, NFKBIA, LIN28A, IFNG, LTF, HSPD1, HSPE1, LTBR]
GO:0015015;heparan sulfate proteoglycan biosynthetic process, enzymatic modification;8.0;1.0;0.875;9.628524252492122;99.84769446867315;7.9853141584524145;0.003341812476775485;0.7833693374183408;[HS3ST3B1]
GO:1903140;regulation of establishment of endothelial barrier;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;90.35426377509846;7.292166977892469;0.003024075894994471;0.747921758369865;[CDH5, IL1B, S1PR3, TNF]
GO:0043407;negative regulation of MAP kinase activity;12.0;0.811012628672052;0.8536266269261705;9.539970855150678;2610.1786565788484;5.4730085344763;0.08736033062741366;0.7280102235641875;[PPP2R1A, NUP62, DUSP2, DUSP1, PAQR3, DUSP6, IL1B, LYN, CAV1]
GO:0015012;heparan sulfate proteoglycan biosynthetic process;8.0;1.0;0.875;9.628524252492122;494.9987824683924;7.004484905440688;0.01656716377923523;0.7332096838060964;[HS3ST3B1, NDST3]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[SPINT2, PHB2, EPHB1, MEF2C, SPINT1, BTK, SFN, LYN, BCL11B, FZD5, CDC6, NOX4, CDKN1A, TNFRSF13B, PRL, PTPRK, BRCA2, CD33, HAVCR2, DUSP1, ARG1, PAWR, PDCD1LG2, CEACAM1, IL1B, TLR2, PTGS2, PAK1, GPNMB, PDPN, CCL23, CDKN2C, LILRB1, LILRB2, PKN1, CD80, SIRPG, TNF, CDH5, DACH1, MEN1, F2R, TPM1, TSC2, HGS, CD274, NACC2, IGFBP7, TGFB1, RARRES3, CAV2, CAV1, HMGA1, DHCR24, INHBA, BCL6, OGN, TNFAIP3, CXCL1, NUP62, PTGIR, MYOCD, TGFBR3, IFNG, XCL1, DLL1, CCL8, CCL2, ZNF503, E2F7, MEIS1, DNAJA3, CD9, FCGR2B]
GO:0042311;vasodilation;8.0;0.7866048967936545;0.7683024483968273;9.148951172230236;40.37281764308888;6.599019797332524;0.0013512418733372556;0.712474179321389;[EDNRB, GCH1, ADRB2]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[EHF, PID1, SPIB, MYB, HOXA3, AKT1, HOXA7, HOXA5, MEF2C, HOXB9, HOXB4, HOXB3, HOXB2, HOXB7, ATF3, HOXB5, NKX2-3, JAG1, JUP, FZD5, PAX5, PAX2, MMP12, ENG, EPCAM, STAT4, NR1H2, ATAD2, GTF2H1, PF4, PLXND1, TNF, MEN1, FOXO1, NFKB1, CXCL10, MAFF, CIITA, HHEX, CEBPE, E2F5, E2F7, KLF5, POU2AF1, CCNH, TNFSF11, DPF3, SLC11A1, EBF1, FLT3LG, RUNX2, BEX1, NHLH2, EGR1, EGR2, EGR3, BCL11B, CD28, PRL, RGMA, IL1B, TLR4, TLR2, LILRB1, IL17A, ARID4A, HOXA10, ADRB2, NLRP3, TGFB1, HMGA1, INHBA, NR4A2, NFKBIA, NR4A1, TCF4, HMGB2, SLC40A1, ARHGEF10L, MYOCD, CKAP2, DLL1, MEIS2, MEIS1, RBMX]
GO:0045824;negative regulation of innate immune response;7.0;0.6240278086381567;0.6629332695762788;8.460919092337061;174.18841360624353;5.970411137910149;0.005829929444006407;0.6562464685024372;[CLEC12B, TNFAIP3, HAVCR2, CR1, ARG1, NR1H2, LILRB1, SERPINB9, MMP12, CEACAM1]
GO:0043525;positive regulation of neuron apoptotic process;8.0;0.8436909121759173;0.7968454560879586;9.392135474427892;179.36331192335928;5.885253329569843;0.0060031286335741505;0.6759721289664703;[FASLG, MYB, IL1B, UBE2M]
GO:0002740;negative regulation of cytokine secretion involved in immune response;10.0;1.0;0.9152410118609203;9.628524252492122;981.2960148552594;7.9853141584524145;0.03284309450812846;0.8236103492792612;[LILRB1, TNF]
GO:0050850;positive regulation of calcium-mediated signaling;8.0;0.7763722522362496;0.7631861261181248;9.283683766200392;239.92176968958296;6.039404009397101;0.008029965715936047;0.6838554019015759;[TREM2, CD3E, TNF, CCL4, TRAT1, P2RX5, CD4]
GO:0032703;negative regulation of interleukin-2 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;6.7325511899570465;0.002184000309729388;0.6674232935401965;[LAG3, XCL1, TNFAIP3, HAVCR2]
GO:2000778;positive regulation of interleukin-6 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;618.0674169630446;6.599019797332524;0.02068616022119099;0.7527151911823093;[F2R, PYCARD, IL1B, TLR8, IL17A]
GO:0051023;regulation of immunoglobulin secretion;8.0;0.8933024483968273;0.8216512241984136;9.523163736834295;116.24681071054106;6.943860283624253;0.0038906761391443723;0.7301093378270707;[TNF]
GO:0071550;death-inducing signaling complex assembly;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;40.42272244673708;7.697632086000634;0.0013529121422039536;0.6838982747154925;[TNF]
GO:0051384;response to glucocorticoid;7.0;0.7671156992804218;0.7344772148974115;9.223059144383958;62.73690238121479;4.800339885259895;0.00209974766315278;0.5964089702280253;[CDKN1A, TNF, GHSR, ANXA1, DUSP1, ANXA3, ARG1, AVPR1A, IL1B, ADAM9, PCNA, ABCB4, PTAFR, PTGS2, FOXO1, IGFBP7, TGFB1, ALPL, SDC1]
GO:0048662;negative regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.58586787906956;5.970411137910149;0.0021281617743466354;0.6284474158353811;[CDKN1A, TNFAIP3, MEF2C, PTGIR, MYOCD, TPM1, IFNG, OGN]
GO:0071677;positive regulation of mononuclear cell migration;9.0;0.8933024483968273;0.8428918493787028;9.533214072687796;295.2864367703214;6.686031174322154;0.009882971298162901;0.7381645703673706;[CCR1, TGFB1, FPR2, PLA2G7, TNF, LGALS3, CXCL10, CXCL12, CCL5, PDGFD, CCL1, CCR2]
GO:0071316;cellular response to nicotine;5.0;1.0;0.7902410118609202;9.628524252492122;116.90797783109151;7.697632086000634;0.003912804807657419;0.6838982747154925;[TNF, NFKB1]
GO:0032269;negative regulation of cellular protein metabolic process;7.0;0.4739867211454891;0.587912725829945;7.449991808168055;289.3917989888356;2.854429736204582;0.009685683076446155;0.4968950347112605;[PID1, SPINT2, AKT1, SPINT1, ATF3, FLRT2, PRKAR2B, SFN, LYN, PKIG, CDKN1A, LRRC4, DUSP2, DUSP1, SERPINB9, PAX5, DUSP6, PAX2, ENG, SERPINB10, LRRC19, PTGS2, DMD, CDKN2C, NR1H2, PKN1, TNF, PYCARD, MEN1, FOXO1, TNFRSF10C, TNFRSF10B, DHCR24, NFKB1, CNOT3, LRRK2, HHEX, CR1, TNFRSF1B, NLRC4, EIF3E, EDNRB, PPP2R1A, FBXO5, IL1R2, PAQR3, MIF, POR, SLPI, NAIP, TNFSF14, PTPRR, CEACAM1, BANK1, IL1B, TLR4, GNAI2, TM4SF20, NLRP12, TSC2, TGFB1, CAV1, CRIM1, LIN28A, TNFAIP3, LRRTM4, NUP62, MYOCD, MMP9, LTF, SPOCK3]
GO:0050852;T cell receptor signaling pathway;10.0;1.0;0.9152410118609203;9.628524252492122;219.43154282413207;4.981283082083729;0.007344176262756358;0.6699840603320352;[DENND1B, CD3G, CD3E, GRAP2, PDE4B, ICOSLG, HLA-DPA1, BTK, HLA-DQB1, HHLA2, PAK1, HLA-DQA1, EIF2B3, HLA-DRB4, TRAT1, BMX, NFKB1, CD4, CD28, HLA-DPB1, HLA-DRA, LAT]
GO:0016579;protein deubiquitination;9.0;0.7307253602413294;0.7616033053009538;9.151600180401813;202.59641706362558;4.174954806800768;0.0067807197541817285;0.6097480081553338;[RUVBL1, SKP2, ADRB2, NLRP3, BARD1, NFKBIA, TNFAIP3, FAM105A, USP9Y, EIF3F]
GO:0033591;response to L-ascorbic acid;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;69.44758579076571;7.9853141584524145;0.0023243481976474804;0.7592887026755414;[IL1B]
GO:0031293;membrane protein intracellular domain proteolysis;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;50.748517158788495;6.8867018697843045;0.0016985071986044009;0.7031056191423581;[TGFB1, PSEN2, NFKB1]
GO:0008053;mitochondrial fusion;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;60.85147907762772;6.943860283624253;0.0020366442419525303;0.6453503496879909;[BCL2A1]
GO:0014050;negative regulation of glutamate secretion;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;415.4544886335298;7.8311634786251565;0.013904887849799128;0.7967266896635242;[IL1B]
GO:0001780;neutrophil homeostasis;6.0;1.0;0.8231203125901445;9.628524252492122;41.67181410794555;8.16763571524637;0.0013947181159950893;0.7408135829017477;[ANXA1, PDE4B, JAM3]
GO:0001660;fever generation;7.0;1.0;0.8509193652572005;9.628524252492122;35.726156595412796;8.16763571524637;0.0011957223097949796;0.7686126355688037;[IL1B]
GO:1901898;negative regulation of relaxation of cardiac muscle;8.0;1.0;0.875;9.628524252492122;64.744883465393;9.083926447120524;0.002166952982974574;0.839552420951524;[PDE4B]
GO:0010803;regulation of tumor necrosis factor-mediated signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;58.00234281560482;5.734022359845919;0.001941286215318787;0.64415753539903;[TNFAIP3, TNF, PYCARD, TRAF1]
GO:0050869;negative regulation of B cell activation;8.0;0.7586651285174919;0.754332564258746;9.158520623246385;160.49678057359853;6.375876246018314;0.005371682808073518;0.701062607729944;[TNFRSF13B, TNFAIP3, SLA2, LYN, PAWR, INHBA, BCL6, BANK1, BTK, PKN1, FCGR2B]
GO:0032496;response to lipopolysaccharide;5.0;0.8933024483968273;0.736892236059334;9.446202695698167;64.414971589946;4.086714173356409;0.002155911129404774;0.4992357647380114;[CD80, CXCL13, PYCARD, EDNRB, GHSR, MEF2C, SLC11A1, CD180, F2R, KMO, SLPI, ADAM9, S100A8, CD274, ABCB4, C5AR1, MGST1, LY96, CSF2RB, TNFRSF11A, KLRK1, STAP1, NLRP3, ELANE, ABCA1, DEFA4, TNFRSF10C, TNFRSF10B, DEFA1, PPBP, SELE, NFKB1, CXCL10, CXCL11, ALPL, CXCL6, CXCL9, HMGB2, TNFAIP3, CXCL1, TREM2, FASLG, CXCL3, CXCL2, CXCL5, PDE4B, CTSG, CD36, CCR5, HAVCR2, PTGIR, ARG1, PDCD1LG2, TNFRSF1B, IL1B, TLR4, CX3CR1, CEBPE, PTGER2, PTGS2, CNR1, CCL2, IL12RB2, GCH1, CCL20, NR1H2, LILRB1, LILRB2, CD6, LTBR, PF4]
GO:0032375;negative regulation of cholesterol transport;8.0;0.7980440201809971;0.7740220100904985;9.271849308553389;149.42902716417655;7.292166977892469;0.005001255061791553;0.747921758369865;[EGF, NFKB1]
GO:2000304;positive regulation of ceramide biosynthetic process;9.0;0.9326813400603323;0.8625812952104552;9.59573442966913;909.7864372675522;7.57984905034425;0.03044973330070948;0.7838744581139225;[TNF]
GO:0035523;protein K29-linked deubiquitination;10.0;1.0;0.9152410118609203;9.628524252492122;204.99431233642397;8.16763571524637;0.006860975150996652;0.8329342821725234;[TNFAIP3]
GO:0071548;response to dexamethasone;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;124.89021324540595;6.015873511986907;0.004179963043429046;0.6826520511697386;[PCNA, ABCB4, PTAFR, FOXO1, GHSR, TGFB1, ARG1, IL1B]
GO:0006366;transcription by RNA polymerase II;10.0;0.6039883530135606;0.7172351883677006;8.613793447804714;583.8786478812184;3.2909128387363804;0.01954189288791682;0.5835384474769965;[EHF, CCNH, SPIB, MYB, HOXA7, HOXA5, MEF2C, HOXB3, HOXB2, HOXB7, ATF3, HOXB5, NHLH2, EGR1, EGR2, BCL11B, PAX5, PAX2, FLNA, GTF2H1, ARID4A, HOXA10, C5AR1, HMGA1, NFKB1, MAFF, MYOCD, CREB5, CEBPE, POLR2E, POLR2I, POLR2J, POLR2L, MEIS2, MEIS1, KLF5, POU2AF1, RBMX]
GO:0048711;positive regulation of astrocyte differentiation;10.0;0.9326813400603323;0.8815816818910864;9.587702257971866;472.09912929902924;7.069023426578259;0.015800732996006494;0.7767511986393403;[IL1B]
GO:0046654;tetrahydrofolate biosynthetic process;8.0;0.9326813400603323;0.8413406700301662;9.603206444507832;1227.4757260734505;7.697632086000634;0.04108250789524529;0.7686572628545723;[ATIC, GCH1]
GO:0006006;glucose metabolic process;6.0;0.7090535922965819;0.6776471087384355;8.572471578242808;34.676020684410545;5.040875179285974;0.0011605752059146955;0.5809109036834981;[TNF, HK3, AKT1, NPY1R, FBP1, ATF3]
GO:0032526;response to retinoic acid;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;43.78950961223322;5.123113277522946;0.0014655954787213788;0.5522372631225753;[PHB2, MYB, IGFBP7, LYN, ABCA1, PDGFRB, DUSP1, TIE1, PAX2, EPHA3]
GO:0002677;negative regulation of chronic inflammatory response;8.0;0.8653626801206646;0.8076813400603323;9.434368238051164;164.0532991907983;8.390779266560578;0.0054907162855322425;0.8041048419030481;[TNFAIP3]
GO:1990168;protein K33-linked deubiquitination;10.0;1.0;0.9152410118609203;9.628524252492122;204.99431233642397;8.390779266560578;0.006860975150996652;0.8443458537639685;[TNFAIP3]
GO:0043392;negative regulation of DNA binding;5.0;0.7586651285174919;0.6695735761196662;8.866384200445225;32.533753988449135;5.788089581116195;0.0010888754675157227;0.5862441822128946;[NFKBIA]
GO:0071850;mitotic cell cycle arrest;7.0;0.8653626801206646;0.7836007053175329;9.420884887713877;120.3495477317274;7.069023426578259;0.00402799105501988;0.7124295520356204;[CDKN1A, DUSP1]
GO:0002439;chronic inflammatory response to antigenic stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;42.97336350789415;8.390779266560578;0.0014382798030929574;0.7522251544931926;[IL1B, TNF]
GO:0034148;negative regulation of toll-like receptor 5 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;354.70667396235325;9.777073627680469;0.011871713162238609;0.896240625180289;[TNFAIP3]
GO:0070886;positive regulation of calcineurin-NFAT signaling cascade;10.0;1.0;0.9152410118609203;9.628524252492122;339.2927284230194;7.004484905440688;0.011355822276687466;0.7734506956670166;[TNF]
GO:0006919;activation of cysteine-type endopeptidase activity involved in apoptotic process;13.0;0.9326813400603323;0.9288956347978027;9.604426700913061;734.4853933519539;5.322726331426962;0.024582565121551242;0.7347594368888992;[FASLG, TNF, PYCARD, F2R, S100A8, NLRC4, HSPD1, NLRP3, TNFRSF10B, HSPE1, NLRP12, P2RX1]
GO:0051447;negative regulation of meiotic cell cycle;6.0;0.6696747006330769;0.657957662906683;8.659123695304018;99.47825147867721;6.8867018697843045;0.0033294475523774256;0.6753065664753021;[DUSP1, BRCA2, MSH2, FBXO5]
GO:0034140;negative regulation of toll-like receptor 3 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;354.70667396235325;8.67846133901236;0.011871713162238609;0.8400575416471059;[TNFAIP3]
GO:0035234;ectopic germ cell programmed cell death;5.0;1.0;0.7902410118609202;9.628524252492122;49.330608194382684;7.9853141584524145;0.001651051061600959;0.6986103492792611;[IL1B, KIT]
GO:0032088;negative regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.61713652769816;5.420364800990877;0.009358533920496976;0.725318020585559;[TNFAIP3, PYCARD, HAVCR2, NLRP3, NFKBIA, NLRP12, CCDC22]
GO:0034144;negative regulation of toll-like receptor 4 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;354.70667396235325;7.697632086000634;0.011871713162238609;0.7898978880348613;[LYN, TNFAIP3]
GO:0090023;positive regulation of neutrophil chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;945.710466239641;6.343086423195323;0.03165207822087823;0.7568146869955557;[CXCL6, C5AR1, CXCL1, PPBP, CXCL3, CXCL2, CXCL5, IL1B, CXCR2, C3AR1, XCL1, CCL19, PF4]
GO:0050805;negative regulation of synaptic transmission;7.0;0.6835726970475526;0.6927057137809769;8.781226392104918;101.84774727695553;5.6339389012889365;0.00340875244433803;0.6390392626740691;[SLC24A1, PLK2, LRRK2, PTGS2, GNAI1, GNAI2, IL1B, TNR]
GO:0090266;regulation of mitotic cell cycle spindle assembly checkpoint;12.0;0.8653626801206646;0.8808016526504769;9.548481544818586;280.44081179639056;7.138016298065211;0.009386101590480495;0.8131587980249038;[DUSP1]
GO:0034142;toll-like receptor 4 signaling pathway;12.0;0.8436909121759173;0.8699657686781033;9.485423408851448;412.6549923027037;6.943860283624253;0.013811191226989502;0.8032296504172152;[ITGAM, LY96, NFKBIA, TLR4]
GO:0010193;response to ozone;5.0;0.9326813400603323;0.7565816818910864;9.541512875502493;79.59609566907567;7.9853141584524145;0.0026640096902085927;0.6986103492792611;[IL1B]
GO:0090263;positive regulation of canonical Wnt signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;236.52854047757646;5.244474134527214;0.007916397387918217;0.6432026511327102;[LRRK2, RUVBL1, JUP, EGF, CAV1, NFKB1, SULF2, LGR4, NAIP]
GO:0038061;NIK/NF-kappaB signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;6.8867018697843045;8.845336528452411E-4;0.6753065664753021;[NFKB1, AKT1]
GO:0043278;response to morphine;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;93.3430750065417;6.280566066213989;0.0031241087171554015;0.6721078059595746;[ABCB4, TACR3, CNR1, IL1B]
GO:0042742;defense response to bacterium;6.0;0.7866048967936545;0.7164227609869718;9.193206181234276;69.6526388451159;4.021331414093558;0.0023312111388408135;0.5287713881179241;[, HP, CXCL13, TNF, PYCARD, IGHG1, IL6R, SLC11A1, RNASE6, RNASE3, CLEC4D, SLPI, S100A8, SEH1L, C5AR1, KLRK1, NLRP3, IGHA1, ELANE, DEFA4, PRG2, AZU1, DEFA1, PPBP, LYZ, IGKV3-20, IGHM, CXCL6, HMGB2, CTSG, CD36, CAMP, HAVCR2, ANXA3, TLR1, IGHD, BPI, TLR5, TLR4, LTF, TLR2, CEBPE, HIST1H2BK, NLRC4, IGKC, CCL20, CARD9, CD4]
GO:1900745;positive regulation of p38MAPK cascade;12.0;1.0;0.9481203125901445;9.628524252492122;1761.632567075866;6.7325511899570465;0.05896025665364957;0.7924232935401965;[IL1B]
GO:0032757;positive regulation of interleukin-8 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;5.948432231191374;0.002183412136085803;0.6273234135236593;[TNF, PYCARD, FFAR2, CD58, ELANE, F2R, TLR1, CD2, IL1B, TLR8, TLR7, TLR5, TLR4, TLR2]
GO:0044130;negative regulation of growth of symbiont in host;7.0;1.0;0.8509193652572005;9.628524252492122;102.69207226600344;7.212124270218933;0.0034370112418783067;0.7197477358342742;[CTSG, CD36, TNF, ELANE]
GO:0031663;lipopolysaccharide-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;6.343086423195323;8.87013979980389E-4;0.647506047256038;[PTAFR, LY96, TNF, CCL5, AKT1, CCL2, LYN, TGFB1, NFKBIA, CD6, IL1B, TLR4, TLR2]
GO:0032870;cellular response to hormone stimulus;5.0;0.6039883530135606;0.5922351883677006;7.932074963068391;80.94247679971589;3.9540277321974506;0.0027090718549867714;0.49245017396659174;[CYFIP1, PID1, AKT1, PTGDR, MEN1, GHSR, LHCGR, MEF2C, POR, ADCY9, SIK1, ABCB4, SLC30A10, FOXO1, PRKAR2B, IGFBP7, GAS2L1, TGFB1, CAV1, CDC6, INHBA, NFKB1, NR4A2, NR4A1, ROBO2, CTSS, GHR, ANXA1, DUSP1, ARG1, GLP2R, AVPR1A, CEACAM1, KIT, PTGER2, P2RY6, PAK1, SORBS1, TSHR, RAMP1]
GO:0034136;negative regulation of toll-like receptor 2 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;354.70667396235325;8.390779266560578;0.011871713162238609;0.8253454670833372;[LYN, TNFAIP3]
GO:0010745;negative regulation of macrophage derived foam cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;114.21841186311113;7.212124270218933;0.0038227874551613377;0.6919486831672181;[ABCA1, NFKBIA, NR1H2]
GO:0006809;nitric oxide biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;241.09966064176743;7.212124270218933;0.008069388666072628;0.6919486831672181;[GCH1, AKT1]
GO:0010744;positive regulation of macrophage derived foam cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;113.85781812010546;7.004484905440688;0.0038107187070962377;0.6813299963962409;[MSR1, AGTR1, CD36, NFKB1, PF4]
GO:0032755;positive regulation of interleukin-6 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;64.94897299966192;5.395046993006588;0.0021737836760178982;0.5990232667078439;[TNF, PYCARD, CD36, IL6R, F2R, TLR1, IL1B, TLR8, TLR7, TLR4, TLR2, PTAFR, HSPD1, CARD9, LILRB2, IL17A]
GO:0030213;hyaluronan biosynthetic process;8.0;1.0;0.875;9.628524252492122;506.6998597758615;7.8311634786251565;0.01695878830643033;0.7754860644832351;[IL1B]
GO:0030335;positive regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.22453031427283;157.26390226612122;3.6656062881777913;0.005263481280523835;0.5383786413027378;[MYLK, LGALS3, C3AR1, AKT1, IL1R1, ACTN4, PFN1, FPR2, PLA2G7, PDGFD, PDGFC, ELANE, LYN, CCR1, TNFSF14, PLK2, PPBP, PTK2, NOX4, NRP1, NRP2, CCR6, CCR2, ANXA1, ANXA3, GAB1, CEACAM6, IL1B, KIT, HBEGF, PTAFR, PTGS2, GNAI2, PAK1, GPNMB, CXCR2, PDPN, FLNA, CCL19, CCL20, PF4, SEMA5B, CXCL13, TNF, SLC8A1, CXCL16, PYCARD, IL6R, PDGFRB, F2R, ADAM9, CD274, CD151, C5AR1, CORO1A, TGFB1, CXCL10, CXCL11, CXCL12, DOCK5, CXCL6, CXCL9, TNFAIP6, LAMC2, CXCL1, CXCL3, CXCL2, CXCL5, MMP9, IFNG, XCL1, P2RY6, CCL8, CCL7, CCL5, CCL4, CCL1, EGF, SEMA4B, TEK]
GO:0035584;calcium-mediated signaling using intracellular calcium source;8.0;1.0;0.875;9.628524252492122;30.117246255164275;6.781341354126479;0.0010079971283984438;0.7217981122146513;[GRM5, CCL20, AZU1]
GO:0070429;negative regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;403.9920680879125;9.777073627680469;0.013521250949646067;0.896240625180289;[TNFAIP3]
GO:0071639;positive regulation of monocyte chemotactic protein-1 production;7.0;1.0;0.8509193652572005;9.628524252492122;88.62106486279957;7.474488534686424;0.0029660672871775788;0.7331650565203278;[IL1B]
GO:0033280;response to vitamin D;7.0;0.9326813400603323;0.8172600352873667;9.548481544818586;74.55580141320215;6.375876246018314;0.002495315577434836;0.6769819729871445;[TGFB1, ABCB4, PTGS2, CXCL10, CD4, IL1B, ALPL]
GO:0051591;response to cAMP;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;79.54904468548885;5.192106149009898;0.0026624349361310785;0.5886448625081389;[PTAFR, AQP9, SLC8A1, DUSP1, KCNQ1, NDUFS4, NOX4, SDC1, TEK, SLC26A3]
GO:1903347;negative regulation of bicellular tight junction assembly;7.0;1.0;0.8509193652572005;9.628524252492122;107.40702245958384;8.390779266560578;0.003594816381677759;0.7800242071602487;[TNF]
GO:1901841;regulation of high voltage-gated calcium channel activity;11.0;0.8933024483968273;0.8790801765280758;9.52844079393514;231.63307343421357;7.212124270218933;0.007752550511611162;0.8012573229067359;[PDE4B, GEM]
GO:0009615;response to virus;5.0;0.7436939687323844;0.6620879962271125;8.801845679307654;27.267803904038782;4.174954806800768;9.126288572378991E-4;0.503748394835965;[CHRM2, TNF, PYCARD, STMN1, IFNA14, IFNA16, RNASE6, RNASE2, IFNA10, NLRP3, IFNA21, HMGA1, AZU1, DEFA1, CXCL10, CXCL12, IFNA5, IFNA4, IFNA7, CXCL9, IFNA2, IFNA8, MMP12, ACTA2, EEF1G, IFNG, TLR8, XCL1, TLR7, UNC93B1, CXCR4, SAMHD1, CCL8, CCL5, CCL4, CCL19, CCT5, CARD9, LILRB1]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[EHMT2, SLA2, MYB, HOXA7, MEF2C, HOXB4, HOXB3, ATF3, PRDM16, ELANE, PKIG, EZH2, PAWR, PAX5, AES, MMP12, NR1H2, TNF, DACH1, MEN1, TLE4, FOXO1, NACC2, WFS1, NFKB1, BCL6, CIITA, FASLG, HHEX, RFC1, RBBP8, E2F7, KLF8, KLF5, DNAJA3, UXT, ZNF608, EDNRB, PCBP3, EGR1, BCL11A, XPO1, CD36, IL1B, CCNE1, TGFB1, CBX4, CAV1, NR4A2, MXD1, MYOCD, IFNG, FBP1, MEIS2]
GO:0010718;positive regulation of epithelial to mesenchymal transition;6.0;0.811012628672052;0.7286266269261705;9.377209824211215;170.70262580884207;5.9928839937622085;0.005713263263432726;0.6295966787287501;[PDPN, TGFB1, IL1B, EZH2, ENG]
GO:0045471;response to ethanol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;69.73224034292265;5.006389003214805;0.0023338753293357085;0.5462679783062231;[EEF1B2, CLDN3, IL1B, CLDN7, S100A8, CCL7, CNR1, GSN]
GO:0097421;liver regeneration;6.0;1.0;0.8231203125901445;9.628524252492122;47.21654787453615;6.250713103064308;0.0015802953652264606;0.6427820713687392;[PCNA, TGFB1, SULF2, NFKBIA, EZH2]
GO:0010956;negative regulation of calcidiol 1-monooxygenase activity;10.0;1.0;0.9152410118609203;9.628524252492122;1348.0729573390952;8.67846133901236;0.045118788695244674;0.8590579283277371;[NFKB1]
GO:0071872;cellular response to epinephrine stimulus;8.0;1.0;0.875;9.628524252492122;410.2922764159275;7.212124270218933;0.01373211325256535;0.7438283705770736;[KCNQ1, PDE4B]
GO:0070423;nucleotide-binding oligomerization domain containing signaling pathway;12.0;0.8933024483968273;0.8947715367885583;9.56183287799345;487.9171050824184;6.481236761676141;0.016330146410222554;0.7795710619905949;[TNFAIP3, NFKBIA]
GO:0070301;cellular response to hydrogen peroxide;6.0;1.0;0.8231203125901445;9.628524252492122;361.02555909653125;5.682729065458369;0.012083200561052132;0.6137353412716126;[PCNA, TNFAIP3, FOXO1, IL18RAP, PDGFD, MYB, ANXA1, ARG1, PAX2, EZH2]
GO:0070427;nucleotide-binding oligomerization domain containing 1 signaling pathway;13.0;1.0;0.9625549647676366;9.628524252492122;488.61025226297863;9.083926447120524;0.01635334542256394;0.9271073857191605;[NFKBIA]
GO:0035335;peptidyl-tyrosine dephosphorylation;8.0;0.8933024483968273;0.8216512241984136;9.52844079393514;179.24922260518233;5.181953777545879;0.005999310166768488;0.6400053571691908;[PTPRR, PTPRK, DUSP2, DUSP1, DUSP6, TPTE, PTPRE]
GO:2000334;positive regulation of blood microparticle formation;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;107.44151918580685;9.083926447120524;0.0035959709560594052;0.7876727335416686;[CD36, TNF]
GO:0032743;positive regulation of interleukin-2 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;6.409777797693995;0.002183412136085803;0.6509166472493662;[CD83, CD80, CD3E, PDE4B, CCR2, ANXA1, CD4, IL1B, CD28]
GO:0035690;cellular response to drug;4.0;0.5629771490299041;0.531488574514952;7.020557509946895;41.90713853914268;4.145861845859104;0.0014025942129290189;0.462019567599527;[TFRC, TNF, SLC8A1, IL18RAP, CDH1, MYB, MEF2C, KCNQ1, BLM, ABCB4, FOXO1, PDGFD, EGR1, TGFB1, JUP, NFKB1, EZH2, LRRK2, TNFAIP3, PDE4B, MAP4K1, ANXA1, ARG1, PAX2, DNM2, IL1B, FBP1, PCNA, PTAFR, PTGS2, GNAI1, CCL7, RAD51, CD69]
GO:0045599;negative regulation of fat cell differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.62387697121986;5.948432231191374;0.0038363580074348307;0.6273234135236593;[TNF, FOXO1, TGFB1, JAG1, SORT1]
GO:0046325;negative regulation of glucose import;8.0;0.9326813400603323;0.8413406700301662;9.548481544818586;84.7654042001006;7.138016298065211;0.0028370217946663582;0.7400384854347593;[PID1, TNF]
GO:0007204;positive regulation of cytosolic calcium ion concentration;11.0;0.6835726970475526;0.7742153008534385;9.097896001429952;290.3013502407617;4.174954806800768;0.00971612493830514;0.645936335304707;[CXCL13, SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, PTGDR, F2R, AGTR1, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, CCR10, CCR1, CAV1, CXCL10, CXCL11, CD24, GPR18, CXCL9, FASLG, CCR9, CCR6, CD36, CCR5, CCR2, CD52, PTGIR, TRPC3, TRPC1, AVPR1A, IL1B, XCL1, CX3CR1, PTGER2, CXCR5, CXCR4, CXCR6, CXCR1, CXCR2, S1PR3, CCL1, CCL19, GPR157, GPR6, P2RX5, CD4, F2RL3]
GO:0030316;osteoclast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;47.07409398820286;6.375876246018314;0.0015755275618510598;0.6491829203200885;[TGFB1, TFRC, TREM2, TNFRSF11A, TNF, OSCAR, TNFSF11]
GO:2000349;negative regulation of CD40 signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;187.41437209568753;9.083926447120524;0.006272590372058239;0.8154717862087246;[TNFAIP3]
GO:0002548;monocyte chemotaxis;7.0;1.0;0.8509193652572005;9.628524252492122;125.46101547564297;6.039404009397101;0.004199067280386423;0.6597747671587765;[CCL13, CCL23, ANXA1, CCL20, TNFRSF11A, LGALS3, CCL8, CCL7, CCL5, CCL4, TNFSF11, CCL2, XCL1, CCL1, CCL19, CCL18, IL6R, CCR2]
GO:0070098;chemokine-mediated signaling pathway;7.0;0.7307253602413294;0.7162820453778652;8.999915593069748;30.19135422731818;5.459585514144159;0.00101047745553359;0.6301228223472235;[CX3CR1, CXCL6, CCL13, CXCL9, CXCR5, CXCR4, CXCL1, CXCR6, CXCL13, CXCL3, CXCL2, CXCL5, CCL8, CXCR1, CCL7, CCL5, CXCR2, CCRL2, CCL4, CCR9, CCL2, CCL1, CCR6, CCL19, CCR5, CCL18, CCR10, CCR2, CCR1, CCL23, CCL20, PPBP, CXCL10, CXCL11, CXCL12, XCL1, PF4]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[PHB2, AKT1, PROK2, MEF2C, CLDN7, SLC30A10, FIGNL1, SFN, BARD1, PLK2, AZU1, CDKN1A, CHL1, ANXA1, DUSP1, ANXA5, SERPINB9, PAX2, PTGS2, UNG, FLNA, CCL19, GABRA5, PF4, TNF, CLEC5A, F2R, MSH2, BLM, CORO1A, FOXO1, WFS1, TNFRSF10C, TNFRSF10B, DHCR24, NFKB1, CXCL12, BCL6, LRRK2, FASLG, TNFRSF1B, ADAMTS20, CX3CR1, LRP1, NLRC4, CCL5, CCL2, TIE1, IL2RB, SLC46A2, LGALS3, TCL1A, EDNRB, EPHB1, FLT3LG, MIF, BTC, POR, EPHA3, NAIP, EGR3, BCL11B, TNFSF14, PTK2, VNN1, CD28, NRP1, CCR5, CEACAM6, IL1B, KIT, GNAI2, CXCR2, PDPN, LILRB1, GRINA, PDGFRB, GHSR, C5AR1, PSEN2, CBX4, CAV1, NR4A2, NFKBIA, HMGB2, SLC40A1, TNFAIP3, NUP62, MYOCD, MMP9, NDUFS3, LTF, BCL2A1, DLL1, HSPD1, TEK]
GO:0043065;positive regulation of apoptotic process;7.0;0.5587538620495764;0.6302962962819887;7.806911820114386;80.91235068524658;3.3969510907807043;0.0027080635610472266;0.5246396020141064;[MYB, AKT1, HOXA5, MEF2C, ATF3, SFN, BARD1, LYN, NOX4, ANXA1, DUSP1, PAWR, DUSP6, AES, PTGS2, FGD4, GSN, BIK, G0S2, TNF, CTGF, PYCARD, F2R, MELK, MAL, S100A8, CD274, FOXO1, NACC2, TNFRSF10B, BCL6, FASLG, NLRC4, CCL5, CCL2, P2RX1, PPP2R1A, SIK1, TP53BP2, TNFSF12, ITM2C, IL1B, CXCR2, SORT1, LILRB1, PPP1CA, NLRP12, PDGFRB, NLRP3, TGFB1, CAV1, INHBA, JMY, UBE2M, MMP9, DNM2, IFNG, BCL2A1, HSPD1, CNR1, HSPE1, LTBR]
GO:0034116;positive regulation of heterotypic cell-cell adhesion;6.0;1.0;0.8231203125901445;9.628524252492122;52.08961109106789;7.212124270218933;0.001743392405611612;0.6919486831672181;[CEACAM6, IL1B, TNF]
GO:2000343;positive regulation of chemokine (C-X-C motif) ligand 2 production;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;89.02652997090885;7.8311634786251565;0.0029796378394510905;0.7514054297404357;[MIF, TNF]
GO:2000347;positive regulation of hepatocyte proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;189.09591637334557;7.8311634786251565;0.0063288701457398545;0.7514054297404357;[TNFAIP3]
GO:0070417;cellular response to cold;5.0;0.8436909121759173;0.712086467948879;9.427853557029971;50.719091001651144;7.697632086000634;0.0016975223316068359;0.6838982747154925;[NFKBIA, FOXO1]
GO:0070536;protein K63-linked deubiquitination;10.0;0.9326813400603323;0.8815816818910864;9.577230958104572;204.99431233642397;6.375876246018314;0.006860975150996652;0.7413036195908642;[TNFAIP3]
